³o¬O¤@½g§¹¥þ©M¯E¹©µLÃöªº¤å³¹
¦ý¦n¹³¤S¦³©ÒÃöÁp ¦]¬°¯E¹©¤]¦P¼Ë¦bµo®i³o®M§Þ³N
¦b³oÓ²{ª÷¼W¸êªºªÑ»ù½pÀq´Á(²qªº)
¤]³\¤j®a¨Ó°Ê°Ê¸£ ¸Ñ¸ÑªÑ»ùªº´e
´N¦p¦P¼ÐÃD
±z·Q¨ì¤°»ò©O?
½Ð¤j®a¦h¦h±·³õ ÁÂÁ±z!
¥Íª«¼Ð°O(Biomarker)¬O§ÜÀù¥P¤¦(Anticancer Drug)¡H
ª¾Ãѳq°Tµû½×²Ä60´Á
³z¹L°ò¦]ÀË´úµo²{Àù¯g¬O¥i¦æªº¡C¦ý¬O±¹ï¦h¦p¤û¤òªº¦UºØ¥Íª«¼Ð°O¡A¤â¤W¨S¦³¨¬°÷¬ã¨s¸g¶Oªº¬ã¨s¤Hû¡An§â¥Íª«¼Ð°O¤ÀªR§Þ³N±a¶i¥«³õ¦¨¬°¯e¯f¶EÂ_ªº¤@Àô¡A¹ê¦b§xÃø¡C
°ò¦]ÅéÂå¾Ç¤£Â_¶i¨B¡A¤Î®Éµo²{¨Ã¥Bºë½T´x±±Àù¯gªº¦´Á¼x¥ü¤£¦A»»¤£¥i¤Î¡C¬ã¨s¡u¤À¤l¥Íª«¼Ð°O¡v(molecular biomarker)¡A¥i¥HÀ°§U§Ú̵o²{¯e¯fªºªì´Á¯gÔ¡A¤]¥i§Y®É¶i¦æ¦³®ÄªºªvÀø¡CµM¦Ó¡A³oÓ¹Ú·Q¦Ü¤µ¤´¥¼¹ê²{¡C
¥þ¥@¬Éªº¹êÅç«Ç³£¦b¿n·¥´M§ä¥i¥Î¨Ó°»´ú¯e¯fªº¥Íª«¼Ð°O¡C¦ý¬On§â³oºØ¥Íª«¼Ð°Oª¾Ãѵo®i¨ì¯à°÷¥Î©ó¯e¯f¶EÂ_¡AÁÙ¦³¤@¬qªø¸ôn¨«¡C¬ü°ê¬F©²ªº¥DºÞ¾÷Ãö¥Ø«eÁÙ¨S¦³§åã¥ô¦ó¤@¶µ¥Î©ó¦´Á°»´ú¯e¯fªº¶EÂ_¸ÕÅçªk¡C
©¬´µÂå®v¡]Harvey Pass¡^»¡¡A¥Íª«¼Ð°O³Ì«nªº¥\¯à¡AÀ³¸Ón¯à«ü©úÀ³·í±Ä¦æªºªvÀø¤èªk©Î¯e¯fªº¯f²zª¬ªp¡C
ÂåÃIJ£·~Æ[¹î®a»¡¡An½T©w¬YºØ¥Íª«¼Ð°O¬O§_¥i¥HÀ°§U§Ṵ́»´ú¯e¯f¡A¤Q¤À§xÃø¡A¨S¦³¤H¯à«OÃÒ³o¨Ç¥Íª«¼Ð°O·|Åܦ¨¯à°÷¦æ¾P¤W¥«ªº¯e¯fÀË´ú§Þ³N¡C¦¹¥~¡AÁÙ¦b¹êÅç¶¥¬qªº¥Íª«¼Ð°OºØÃþÁc¦h¡An¿ï¥X¤@ӳ̦³µo®i¼ç¤Oªº¼Ð°O¡A¤]¤£®e©ö¡C
Âå®v³£§Æ±æ³oºØ¥Íª«¼Ð°OÀË´ú¯à°÷À°§U¥Ļä¨ì¹ï¯S©w¯f±w¦³®ÄªºÀøµ{¡C°ÝÃD¦b©ó¡A·í³o¨Ç¥Íª«¼Ð°O¥u¯à¥Î©ó¯f±¡¶EÂ_«oµLªk©ú½T«ü¥XªvÀø¤èªk®É¡AÂå®v¬O§_Ä@·N±Ä¥Î¡C
¬ü°ê¯Ã¬ù¤j¾ÇÂå¾Ç¤¤¤ß±Mªù¬ã¨s¶¡¥ÖÀù¡]mesothelioma¡A¯Ý¸¡µÄ¤ºÅ¨²Õ´ªº´c©Ê¸~½F¡^¥Íª«¼Ð°OªºÂå®v©¬´µ¡]Harvey Pass¡^»¡¡A¥Íª«¼Ð°O³Ì«nªº¥\¯à¡AÀ³¸Ón¯à«ü©úÀ³·í±Ä¦æªºªvÀø¤èªk©Î¯e¯fªº¯f²zª¬ªp¡C
¤C¦~«e¡A¬ü°ê°ê®aÀù¯g¬ã¨s©Ò¦¨¥ß¤F¡u¦´Á°»´ú¬ã¨sºô¡v¡]EDRN¡^¡A§Æ±æÂǦ¹½T»{¥Íª«¼Ð°O§Þ³Nªº¥i¾a«×¡A«Ø¥ß¤@®MÀË´ú»PÅçÃҥͪ«¼Ð°O¬O§_¦³®Äªº¬yµ{¬[ºc¡C³oÓ¤uµ{¬Û·í¯E¤j¡A¦]¬°¯e¯f¶EÂ_ÀË´ú³q±`»Ýn¦P®É¹B¥Î¦n´XºØ¤£¦Pªº¥Íª«¼Ð°O¡A¤~¯à½T«OÀË´úµ²ªG¦b²Îp¤W¬O¦³ÅãµÛ·N¸q¡C
´ú¸Õ¶i¦æ¤¤
EDRN³oÓºô¸ô´£¥X¤@Ó¦p¦óµû§P¥Íª«¼Ð°O¬O§_¦³®Äªº¯ó®×¡A¤]«ü¥X¤F¦UºØ¦³Ãö¼h±¡CEDRN¦b¦¨¤d¤W¸UºØ¼ç¦b¥Íª«¼Ð°O¤¤¿ï¥X¤F¤@¦Ê¤ÜºØ¡A³o¨Ç¥Íª«¼Ð°O¤]¦U¦b¤£¦Pªº¬ãµo¶¥¬q¡C
³o¤@¦Ê¤ÜºØ¥Íª«¼Ð°O¡A¬O¶¡¥ÖÀù¡B¨xÀù¡B»H¯ÖÀù¡BÄáÅ@¸¢Àù»PªÍÀù³o¤ºØÀù¯gªº¥Íª«¼Ð°O¡A¦³ªº¤´¦b¬ãµoªº²Ä¤T¶¥¬q¡A¦³ªº¤w¸g¶i¤J³Ì«á¶¥¬q¡A¨Ã¥B³z¹L¤j³W¼Òªº¤HÅé¸ÕÅçÁA¸Ñ¨ä°»´ú¯e¯fªº®ÄªG¦p¦ó¡C
¬ü°ê°¨¨½Äõ¦{¥Íª«¬ì§Þ¤½¥qCangen Biotechnologies¤]°Ñ»P¤FEDRNpµe¡A¥ĻӦb¦¨¬°²Ä¤@Ó§âDNA¬°°ò¦ªº»H¯ÖÀù¦´Á°»´ú§Þ³N±À¤W¥«³õªº¤½¥q¡C¸Ó¤½¥qªí¥Ü¡A¥L̹ï¦Û¤v¬ãµo¡B¥H¤Q¤ÓDNA¤ù¬q²Õ¦¨ªºÀËÅç¤u¨ã«Ü¦³«H¤ß¡A³oºØÀËÅç¤u¨ã¥i¥H¤ñ¨ä¥L¶EÂ_¤è¦¡§ó¦µo²{¸~½F¡C
¤£¹L¡AÁöµMÂå®v¥i¥H¥Î³oºØ¤u¨ã§ó¦µo²{¸~½F¡A¤j³¡¤Àªº»H¯ÖÀù±wªÌÁÙ¬O±o¸g¾ú¤â³N¡C´«¨¥¤§¡A³oºØ·sªºÀËÅç¤u¨ã¹ï©ó»H¯ÖÀù¯f±wªº¦s¬¡²v¥u¦³»´·L¼vÅT¡C
Cangen¤½¥q¬ã¨s³¡ªù¥DºÞ¦ãºqªi¡]Eddy Agbo¡^»¡¡A³z¹L¥Íª«¼Ð°O§ä¥X¥i¥HªvÀøªì´Á¸~½Fªº·sÃĪ«Àøªk¡A¬O¥LÌ¥¼¨Óªº¬D¾Ô¡CµM¦Ó¡A¥Ñ©ó³oºØ·s¦¡ÃĪ«ÀøªkÁÙ¨S°Ý¥@¡A¬ü°êªºÂå®v»P¤ä¥IÂåÀø·ÓÅ@¾÷ºc¶O¥Îªº«OÀI¤½¥q¡A¹ï¥Íª«¼Ð°Oªº¿³½ì·|«Ü¦³¡C
»sÃIJ£·~¸ê·½Â×´I¡A¤]³\¯à¨Ï¥DºÞ¾÷Ãö§åã¥Íª«¼Ð°OÀË´ú§Þ³N¡C¤£¹L¡AÃļt¤ñ¸ûÃö¤ßªº¡A¬O¦p¦ó³z¹L¥Íª«¼Ð°OÁA¸Ñ±wªÌ¾A¤£¾A¦X¨Ï¥Î¬YºØÃĪ«¡AÃļt¹ï¦´Á°»´ú¿³½ì¯Ê¯Ê¡C
¥[¦{Genentech¤½¥q¬ãµo¥X§Ü¨ÅÀùÃĪ«Herceptin¡A¬OÓ¦¨¥\®×¨Ò¡CHerceptin¦®¦bªvÀø¨º¨ÇÅ餺¹L«×ªí²{¬YºØ¨üÅ骺¨ÅÀù±wªÌ¡C¥ú¬O¥h¦~¡AHerceptin´N½æ¤F¤Q¤T»õ¬ü¤¸¡C
microRNAs
¦è¶®¹ÏºÖ·ç¼w»®ª÷´ËÀù¯g¬ã¨s¤¤¤ß¤À¤l¥Íª«¾Ç®a«¢«n³\¡]Sam Hanash¡^»¡¡A¤j®a³£§Æ±æ¬Ý¨ì¥Íª«¼Ð°O§Þ³N¥X²{À¸¼@©Êªº¦¨¥\¡C«¢«n³\»¡¡A²~ÀV¤£¦b©ó¹êÅç«Ç¸Ìªº¬ì¾Ç¬O§_¥ý¶i¡A¦Ó¬O¬ã¨s¤Hûn¦p¦ó¦b¨º»ò¦hºØ°ò¦]¡B³J¥Õ½è»P·LRNA¡]microRNAs¡^¤¤¥h¿¾¦sµ×¡A§ä¥XÁ{§É¤W¦³¹ê¥Î»ùȪº¥Íª«¼Ð°O¡C¥L»{¬°¡A¥Ø«eªºª¬ªp´N¹³¬O¬ü°ê¦è³¡©Ý¯î®É¥N¡A¨CÓ¤H³£¯à«Å¥Ü¾Ö¦³¤@¤ù¤g¦a¡A¨CӾǪ̤]³£¯à«ÅºÙµo²{¬YºØ¥Íª«¼Ð°O¡C
¥ß¤U¼Ð¬ñ
EDRN¶O¤F¤@µf¥\¤Ò´M§ä³Ì¦³¼ç¤Oªº¥Íª«¼Ð°O¡A¦nÅý³o¨Ç¥Íª«¼Ð°O¶i¤JÁ{§É¸ÕÅç¶¥¬q¡CEDRN¤w¯à´£¨Ñ¥Î©ó¬ã¨sªÍÀù¡B¨ÅÀù¡B§Z±_Àù¡BÄáÅ@¸¢Àù©Mµ²¸zÀùµ¥Àù¯g¥Íª«¼Ð°OªºÀù¤Æ²ÓM²Õ´¡B¦å²M»P¦å²G¼Ë¥»¡C¬ì¾Ç®a¥i¥H¥Î³o¨Ç§÷®Æªì¨BÀËÅç¥Íª«¼Ð°Oªº¥i¾aµ{«×¡C
EDRN¤]«Ø¥ß¤FÅçÃҥͪ«¼Ð°O´ú¸Õ®ÄªGªº«~ºÞ¼Ð·Ç¡A¦³¤@¾ã®M§e²{¸ê®Æªº¼Ð·Ç¨t²Î¡CEDRNÁÙ»P¬ü°ê°ê®aÀù¯g¬ã¨s©Òªº¨ä¥L¹Î¶¤µÛ¤â«Ø¥ß¤@Ó¤j³W¼Òªº¤HÅé¥Íª«¼Ë¥»Àx¦s®w¡]human biosample collection¡^¡C
±M®a»{¬°¡A³o¨Ç¨BÆJ½T¹ê¦³¨ä¥²n¡A¦ý¬O³o¨Ç§@ªk¤£¤@©w¯à§â¥Íª«¼Ð°O´ú¸Õ±a¨ì¥«³õ¤W¡C¦b³Â¦{¥¬¬¥¼w¬ã¨s©Ò¡]Broad Institute¡^¬ã¨s³J¥Õ½èÅ骺¦N¥ß¯S¡]Mi
ÁÂÁ±z!
«¢! «¢! «¢! ¯uªº¤ß±¡«Ü´Î
ÁÂÁ±z
¤j¹Ù£¸©wn«O«¨Åé
µ¥¸Ñª¼¡BÅý¤K°êÁpx¨Ó©ïÃâ
¥ú¥Î·Qªº´N§Ô¤£¦í°½¯º¤F
§Æ±æ²q·Q¤j¨C¤Ñ¤]¯à¶}Ãh¤j¯º´X¦^¡ãÅ¥»¡¹ï°·±d«Ü¦³À°§U©O¡I^_^
Faith ¤j
¥¤ß¦Ó½× ¤j ¨â¦ìªºÃö¤ß
¸g¹L´X¥G¤@¦~ªº¬ÝÂåÀˬd ²{¦b¹ï¦Û¤vªº¨¤ßª¬ªp ¤ñ¥¼µo¯f«e¤F¸Ñ
¦]¬°¤p§Ì±q¦~»´¨ì¦~ªì¥¼µo¯f«e ¤£¹B°Êªº¤é¤l ©}«ü¥i¼Æ
µo¯f¤§ªì ±`¶]«æ¶E ´X¦¸ªº¦å²GÀˬd ³£¥¿±`
§Ú¤Ó¤Ó´N»¡§Ú¥i¯à¬O®£·W¯g(¦]¦oªB¤Í¤¤¦³¤H¦³¦¹¯gª¬)
¦ý¤p§Ì©MCliff ¤jªº·Qªk¤@¼Ë ¤£¯à«_µM¤£Àˬd¨Åé ´Nª½±µ¬Ýºë¯«¬ì
©Ò¥H¦b¤@³s¦êªºÀˬd¤§«á ¤~¶}©l±µ¨üºë¯«¬ìªvÀø
¤§«eªº¤KÓ¤ë®É¶¡ ³£¦Y¤ß«ß½Õ¾ã©M§ÜµJ¼{ªºÃÄ
µM¦Ó¸ÓÃÄÁö¬O·í¤¤³Ì»´ªº ¤ß²v¤]±±¨îªºÁÙ¦n ¦ý°Æ§@¥Î´N¬O¤ß²v¹LºC ¨C¤ÀÄÁ¦b50¤W¤U
¦³®É¨ÌµM¯Ý´e ÀYµÈ ´«Àô¹Ò´N¤£µÎªA
¦³¤@¦¸¦b¦¨¤j°µ²Ä¤G¦¸¹B°Ê¤ß¹q¹Ï ¦]Âå®v¬°¤F¯u¹ê¤F¸Ñ¤ßŦ¥¼¦YÃĪºª¬ªp ³W©w§Ú24¤p®É«e¤£n¦YÃÄ
µ²ªG§Ú´N¶}©lµJ¼{ µ¥¤W¨ì¾÷¾¹ ®Ú¥»ÁÙ¥¼¶}©l´ú¸Õ ¤p§Ìªº¤ß¸õ´N¤wöt¨ì150 ¤£¾A¦A´ú
²{¦bºë¯«¬ì¥ÎÃĤwªñ¨âÓ¤ë ¤ßŦ¤º¬ì¥ÎÃÄ ¤w°±¦Y¤ß«ß¤£¾ãÃÄ ¥u¦Yªü¥q¤ÇÆF
·Pı¤W¦n¹³¦³®ÄªG ¯Ý´eÀYµÈªº±¡ªp¤Ö«Ü¦h ¤ß²v¤]±±¨îªº¤£¿ù ¬ù¦b65~70¶¡
¦P®É ¦b¹B°Ê«áªº½w©M®É¶¡¤]ÁYµu«Ü¦h
´Á«Ý¦b«e±´X¦ì¯E¤Í©Ò´£¨Ñªº¥\ªk©ÎÀøªk ¦b½m²ß¤Wy¹D«á
¯à°÷¥h°£¹ïÃĪ«ªº¨Ì¿à
ÁÂÁ¤j®aªºÃö¤ß
¤j®a¤]n¦n¦n«O¾i¦Û¤vªº¨Åé ¨É¨ü°·±d¤S¦³°]´Iªº¤H¥Í
ÁÂÁ¤j®a!
ÂåÀø¯gª¬§Ú¤£À´¡A¤£¹L¦pªG¦èÂåµLªk¸Ñ¨M°ÝÃD
¬O§_¸Õ¸Õ¶Ç²Î¤¤Âå©Î¥Á«UÀøªk¡H
¥ò´º¤j¥X°ê²`³y³o»ò¤[¡A¸Ó¦^°ê¤F¡A¯à§_´£¨Ñ«ØÄ³¡H
Á`¤§§Æ±æ±z¨Åé±d°·¡A¤£¨ü¯fµh©ÒÂZ¡Aª©¤W¯E¹©ªº¦P¾Ç¤]¤@¼Ë¡A³o¼Ë¦pªG¬Y¦~·í¯E¹©5112®É¡A¤j®a´N¨Ó¶}Ó²±¤jªº¦P¾Ç·|§a
¤p§Ì¤§«e¬Ý±z´yzªºª¬ªp
£¸ª½¹ï±zªº¤ßŦ¸õ°Ê·P¨ì¼~¤ß
¬Q¤é¤Í¤H¨ì®a§@«È¡A²á¨ì°·±d¡A¤]²á¨ì¤ßŦ°ÝÃD
·Pı¡u¤ß©ÐŸ°Ê¡v¬O¤@¯ë¤H¤ñ¸û¤Öµo²{ªº¡A¥H¤U¦³¨Ç¸ê®Æ¨Ñ±z°Ñ¦Ò
¤ß«ß¤£¾ã¤£ªvÀø¡@·í¤ß¸£¤¤·¡Ï¤ßŦ°IºÜ
°·±dÂåÀøºô
11¤ë21¤é¶g¤» ¤W¤È8:16
¡i2016»O¥_´í¥´¤½¯q°¨©ÔªQ¡j
¡]°·±dÂåÀøºô¡þ°OªÌ³\ºÓ¿o³ø¾É¡^¥x¥_ºaÁ`¬ã¨s¹Î¶¤µo²{¡A¦]¤ß©ÐŸ°Ê©Ò¤Þ°_ªº¤¤··ÀI¡A¤ñ¦è¤è¤HÁÙ°ª¡I¬ã¨s«ü¥X¡A¦b¥xÆW¡A¤ß©ÐŸ°Êªº¯f±w¥un±a¦³¤@Ó¤¤·ªº¦MÀI¦]¤l¡A¤¤·¾÷²v´N¤É°ª¬ù3%¡A¬O¦è¤è¤Hªº2¿¥H¤W¡A¦Ó¨ä¤¤¡A·ÀI³Ì°ªªº´N¬O65·³¥H¤WªºªøªÌ¤Î¿}§¿¯f±wªÌ¡C
¥x¥_ºaÁ`¤ßŦ¤º¬ìÂå®v»¯¤l¤Zªí¥Ü¡A¤ß©ÐŸ°Ê¬OÁ{§É¤W³Ì±`¨£ªº¤ß«ß¤£¾ã¡A¥Ø«eµo¥Íì¦]¤£©ú¡C©Ò¿×¤ß©ÐŸ°Ê«Y«ü¤ß©Ð§Ö³t¦Ó¤£³W«ßªº¸õ°Ê¡A¥i©Èªº¬O¡A¦]¤ß©ÐµLªk¦³®Ä¦a¦¬ÁY¡A¤@¥¹µo¥Í¤ß©ÐŸ°Ê®É¡A¤ß©Ð¤ºªº¦å²G¬y°Ê¤£¨Î¡A®e©ö¾®µ²¦¨¦å®ê¡AY¬O¦å®êÀHµÛ¦å²G¬y¦V¸£³¡¡A¥i¯à·|ªý¶ë¦í¸£³¡¦åºÞ¦Ó¤Þ°_¸£¤¤·¡C
¥_Á`¤ß«ß¤£¾ã¬ã¨s¹Î¶¤¦¨û¡B·sÃÄÁ{§É¸ÕÅ礤¤ß¥D¥ô¦¿±á®¦±Ð±Âªí¥Ü¡AÁöµM¼Ú¬üªºªvÀø«ü¤Þ§¡«ØÄ³n¨Ï¥ÎÃĪ«¨Ó±±¨î¯f±wªº¤ß¸õ³t²v¡A¦ý¥Ø«eµL¥ô¦óªº¤åÄm©ú½T«ü¥X¤ß²v±±¨î¥i¥H§ïµ½¯f±wªº¹w«á¡C
¤ß©ÐŸ°Ê¤£±±¨î¡@©ö¤¤·¡B¤ßŦ°IºÜ
¥Ø«e¥xÆW¤ß©ÐŸ°Ê²±¦æ²v¬ù1%¡A¥þ¥x¬ù¦³23¸U¦W¤ß©ÐŸ°Êªº¯f±w¡A¦Ó¤ß©ÐŸ°Ê¤]±`¦X¨Ö¤ß¸õ¹L³t°ÝÃD¡AY¤£±±¨î¯fªp¡AÅý¤ßŦt¾á¤j¡A®e©ö¦³°IºÜªº¦MÀI¡A¦]¦¹¡AÂå®v«ü¥X¡A±±¨î¦í¤ßŦ¸õ°Êªº³t«×¡A¥i¹w¨¾¤¤·¡A¤]¥iÁ×§K¤ßŦt¾á¹L¤j¡C¦¹¬ã¨s¤w¥Zµn©ó¤ßŦ¾Ç¬É«¶q¯Åªº´Á¥ZJ Am Coll Cardiol»PCirculation¡A°ê»ÚÂå¾Ç´CÅéMedscape§ó¬O±MÃD³ø¾É¡C
ÃĪ«±±¨î¤ß¸õ¡@¥i°§C¦º¤`·ÀI
2013¦~®É´¿¥H¤ß©ÐŸ°Ê¹q¿N³N¬°¥DÃDºaÀò¥Íµ¦·|SNQª÷¼úªº¥_ºa¤º¬ì³¡³¯¾A¦w¥D¥ô¬O¬ã¨s¹Î¶¤ªº»â¾ÉªÌ¡A¥D¥ôªí¥Ü¡A¬ã¨s¹Î¶¤¦b¨â¦~¶¡¡A¤ÀªR¤Fªñ30¸U¦W¤ß©ÐŸ°Ê±wªÌ¡A¬ã¨s¤£¦P¤ß²v±±¨îÃĪ«¹ï©ó¯f±w¹w«áªº¼vÅT»P¤¤·¾÷²v¡C¬ã¨sµ²ªGÃÒ¹ê¡A±µ¨ü¤A«¬ªýÂ_¾¯¨Ó±±¨î¤ß¸õ³t«×ªº¯f±w¡A¬Û¸û©ó¨S¦³¨Ï¥Î¥ô¦ó¤ß²v±±¨îÃĪ«ªº²Õ§O¡A¦º¤`ªº·ÀI¬ù¤U°24%¡C¦Ó¨Ï¥Î¤ò¦a¶À¨Ó±±¨î¤ß²vªº±wªÌ¡A¤£¦ýµLªk¦³®ÄªvÀø¤ß«ß¤£¾ã¡A¤Ï¦Ó´£°ª¦º¤`·ÀI¡]¬ù12%¡^¡C
ªøªÌ¡B¿}§¿¯f°ª·ÀI¡@ÂåÆ~¿n·¥ªvÀø
¦P®É¡A¥_ºa¹Î¶¤§óµo²{¡A¥xÆW¤ß©ÐŸ°Ê±wªÌªº¤¤··ÀI¦ü¥G¤ñ¦è¤è¤H°ª¡A¥un±a¦³¤@Ó¤¤·ªº¦MÀI¦]¤l¡A¸£¤¤··ÀI±Û§Y¼W¥[2.55%¨ì2.75%¡A¬O¦è¤è¤Hªº2¿¥H¤W¡A¨ä¤¤¡A¤S¥H¦~¬ö¶W¹L65·³¤Î¿}§¿¯f±wªÌªº·ÀI³Ì°ª¡C»¯¤l¤ZÂå®v©IÆ~¡AY¦³¤Wz±¡ªpªº±wªÌ¡AÀ³ªø´Á±µ¨ü¤fªA§Ü¾®¦åÃĪ«ªvÀø¡A¥H¹w¨¾¤¤·ªºµo¥Í¡C
ÁÂÁ±z´£¥Ü½m¥\¤ßªk ©ÎÅý¨S¤°¼z®Úªº¤p§Ì¤ñ¸û®e©ö¶i¤Jª¬ªp
·PÁ±zªº¤À¨É
QQ¤j
ÁÂÁ±zªº¸É¥R
¤p§Ì·|¸ÕµÛ±q¤j®aªº¤èªk¤¤¥hÅé·| §ä¥X¾A¦X¤p§ÌÅé½è¯fªpªº¤è¦¡ «ù«í½m²ß
ÁÂÁ¤j®aªºÃöÃh
¦A¦¸¯¬ºÖ¤j®a¨¤ß°·±d ¤ß·Q¨Æ¦¨
©êºp! §Ñ°O´£¤Î«á¨Ó§Ú¨Ï¥Î¦å¿}µ§¨ú¥N©ñ¦å¤ù. ¸û¦³®Ä²v, ¬}¤f¤]¸û¤p.
¤w¼Æ¦~¨S¦³³o¡¨¦å½ÄÀY¡¨ªº§xÂZ¤F.
¥t¤p©_¤j©Ò»¡ªºì©lÂI, Y¤£¤è«K«ö¼¯®É, ¥ÎÂåÀø¯Åªº»·¬õ¥~½u·Ó®g¤]«Ü¦n.
®ÄªG¦U¦³¤d¬î. ¦Ü©ó3¸U¥ñ¯Sªº¹q¦ìªvÀø´È¹ï©ó¨Å骺¯«¸g½Õ¾ãªø´Á¤U¨Ó·|
¦³À°§U. ³o¨Ç³£¬OÓ¤H¤Î¿Ë¤Í¸gÅç¤À¨É¨Ñ±z°Ñ¦Ò.
´µ¤p¤å¤j:
+ 1
¥H¤U¬O¤p§Ì©Ò±µÄ²ªº¨ä¤¤¤@ªù®ð¥\¡A°w¹ï®ð¥\ºAªº»¡©ú¡A¥i°Ñ¦Ò¬Ý¬Ý
®ð¥\ºA¡G¤w¶i¤J©ÀÀY±M¤@¡A¤ß«Ü¦wÀR¡A¦w©wªº½m®ðª¬ºA¡AºÙ¬°¡i®ð¥\ºA¡j¡C³oºØª¬ºA·|¨ÏÂø©À¦ÛµM®ø¥¢¡A¦p¦P¶i¤J¤F¤£¦Pªº®É¶¡¡BªÅ¶¡¦¸¤¸¡C
¡u§Ún¶}©l½m¥\¡A¶i¤J®ð¥\ºA¡vªº¦Û§Ú·t¥Ü¡A¥i¥H¨ó§U¶i¤J®ð¥\ºA
½m®ðªº®ÉԤ߫ܦwÀR¡B¦w©w¡A¤ß´N±Ó¾U¡A»E¶°®ðªº¯à¶q¤~·|ºë¯Â¡C¦Ó
¥B¼ô±x¤ñ¸ûºë·Lªº®ð·P«á¡A¤ß§ó®e©ö©w¡C
¤p§Ì·|·ÓµÛ°µ°µ¬Ý
§Æ±æ¦hºÞ»ô¤U ¦¤é«ì´_°·±d ÁÂÁ¤j®a!
JM¤j
±zªºÀR§¤«ØÄ³ ¨Ìºa¶§ªº¬ã¨s¦ü¥G¥i¥H¬¡µ¸°Æ¥æ·P¯«¸g §Ú·|¸ÕµÛ½m²ß¬Ý¬Ý
ÁÂÁ±z
Cliff ¤j
±z¯u¬O¸U¨Æ³q ³s¥\ªk³£¬ã¨s»á²` ¤@»y¹D¯}½m¥\ºëÀH
¡§®ð¥\ºAªºª¬ªp¤U¡A¨¤ß¬O³B©ó»´ÃP¡B´r§Ö¡BÃP¡BÀR¡B¦ÛµM¡A¹ï©ó½Õ¸`¦Û«ß¯«¸g¡AÓ¤H¸gÅçı±o¦³©ÒÀ°§U¡¨
«¢! ì¨Ó¤p§Ì¥H«e°µªº³£¬OÅé¾Þ
¤p§Ì¤]ı±o¦Û¤v¤ß«ß¤£¾ã¬O¯gª¬ ¤£¬O¯f¦]
§Ú¦³°µ¹B°Ê¤ß¹q¹Ï ¦ý¦]¤p§Ì¦h¦½Åé½è ¦½¬y¤Ó¦h ¼vÅT¶K¤ù»P¨Å骺¶K¦X«×
¾ÉP¹B°Ê¤ß¹q¹Ï ¤£¬Æ²z·Q ¤£©ö§PŪ
¥B·íªì¦]¦Û¤vè°µ§¹PET/CT ¿ç®g¾¯¶q¤w§l¦¬¤£¤Ö ¤£´±¦A°µ¤ß¦ÙÄéª`³y¼v©Î64¤ÁCT«aª¬°Ê¯ßÀˬd
´N¦b¥b¦~«á ¦b¦¨¤j¦í°|Àˬd®É °µ¤F256¤ÁCT«aª¬°Ê¯ßÀˬd
¶t¤Æ«ü¼Æ 0.6 ÁÙ¦n ¦³¦h³B´³¶ô ¦³¨â³B¯U¯¶25 ~ 49 % ¾l¬Ò¤p©ó 25 % À³¤]ÁÙ¦n
¦Ü©ó¸~½FÀ£¢¤¤¼Ï¯«¸gªººÃ¼{ §Ú¦³©çÀV´ÕX ¥ú ¨S²§¼Ë
©ç§C¾¯¶q¯Ý³¡CTªº³ø§i ¦³´£¤Î¡¨ Degenerative change of spine with spurs formation. ¡§ ³oÓ¤£ª¾¦³µL¼vÅT?!
§Úªºª½Ä±©M§Ú¦Yºë¯«¬ìÃĪ«ªº·P¨ü ©Î³\ÁÙ¦³¨ä¥Lì¦] ¦ý°Æ¥æ·P¯«¸g¤Ó®z À³¤]¬Oì¦]ªº¤@Àô
ÁÂÁ±z
QQ¤j
·Q¤£¨ì±z¤]¦³¦P¼Ë¸gÅç ¤p§Ì¬Ý¹L¨âÓ¯«¸g¤º¬ìÂå®v
ÀYÀV³¡MRI ÀV´ÕX ¥ú ÁÙ¦³ÀV°Ê¯ß¶Wµªi ³£¥¿±`
¦ýÀY³¡¯gª¬ÁÙ¬O¨S§ïµ½ ¤@ÓÂå®v´Nª½±µ¸ò§Ú»¡ ¤£¬O³o¬ìªº°ÝÃD ½Ð§ä§O¬ì
¥t¤@¦ì»¡¥i¯àÀV³¡¦Ù¦×¤Óºò ¶}µ¹§Ú¦Ù¦×ÃP¦¢ÃÄ»I
¨C·í§Úı±oÀYµÈµÈ¤£µÎªA®É ¶î©ÙÀV³¡ ¦³½w¸Ñ¤§®Ä
¤ÓµhW¤F ¤£¬O¬ÝÂåW ¦Ó¬O§ì¤£¨ì¯f¦]
ÁÂÁ±z
¦n¤ß¤j
±z¨£¥~¤F ¬O¤p§Ìn¸ò±z¹Dºp¤~¬O
±z»¡¤ß¸Ìªºµ² ÄÝ©ó¤ßÆF¼h±ªº°ÝÃD ¤p§Ì·|ÀR¤ß¦a·Q¤@·Q Äpµ²¦bþ¸Ì
¥Í¯f¤~ª¾¨¤ßÆF¥¿ÅªºÃø³B
ÁÂÁ±z
¦h¦h ¤j
ÁÂÁ±zªº´£¿ô
¡§ ¯uªºn¹ï¯g¤UÃÄ ¡¨ ³o¥¿¬O¤p§Ì·í¤U·Q´M¨Dªº
¬Ý¨ÓÁÙn¤@¬q®É¤é·Î¼õ ¤~¯à§ä¨ì¯u¥¿ªº¯f¦]
ÁÂÁ±zªº¯¬ºÖ
¯E§b ¤j
¤p§Ì¤]¬Ý¹L¥t¤@Ӻ믫¬ìÂå®v
¥L¤]»¡§Ú¬O®£·W¯g
¤£¹L¦Y¤F¶}ªºÃÄ ´X¥G¾ã¤Ñ©ü¨I¨I ´N¤£´±¦A¦Y¤F
©Î³\¬O®£·W¯g ¦]§Úªº¯gª¬¤Ó¹³®Ñ¤W´y¼gªº
¥u¯à¤@¨B¤@¨B¨Ó¬d
ÁÂÁ±z
¦Ñ´ ¤j
ÁÂÁ±zµ¹ªº«ØÄ³ ³o¨â¶µ¤p§Ì¤]³£°µ¤FÀˬd
¤p§Ì¬Q¤é¨S»¡²M·¡ ·Ð³Ò±z¦A¦¸¥mÀ{ ¯u¹L·N¤£¥h
ÁÂÁ±zªºÃö¤ß©M¯¬ºÖ
¤p©_¤j
³Â·Ð±zªá³o»ò¦h®É¶¡ ¸ò¤p§Ì»¡©ú±zªº¸gÅç©MÀøªk
§Ú·|ÂùºÞ»ô¤U¸Õ¸Õ¬Ý ºÉ¤O¦a°õ¦æ
§Æ±æ¯à°U±zªººÖ ¦³®Ä ¬Æ©Î²¬Â¡
ÁÂÁ±z
¦A¦¸·PÁ¤j®aªºÃöÃh ¤p§Ì»Ê·P¤¤º
¥H¤U¬°¤F¨³³t¡B½T¹ê¦aªí¹F¤p§Ìªº·Qªk¡A¤å¦r¤º®e´N¤£°µ¹L¦hªº×¹¢¡C
¥H¤U¬O¬°¤F¯S®í¥Øªº(²q·Q¤j«ì´_°·±d)©Ò°µªº¤Á½R°Q½×¡A»P¬ì¾Ç«D¬ì¾ÇµLÃö¡B»P»ùÈÆ[µLÃö¡B»P¹ï¤¤Âå©Î¦èÂ媺°¾¦nµLÃö¡AY¯E¤Í¦³¿³½ì¥i¦Û¦æ¬ã¨s¡AY¨S¦³¿³½ì´Nª½±µ¸õ¹L¡A¤p§Ìªº°ß¤@¥Øªº¬O²q·Q¤j«ì´_°·±d¡C
½t°_¡G¤p§Ì¦~»´®É³ßÅw¹B°Ê¡A¹B°ÊÃø§K·|¦³¨Ç¹B°Ê¶Ë®`¡A¦ý¦~»´®ð©ô¡A¶KÓ»IÃĹL¤@°}¤l¤]´N¤£Ãª¨Æ¤F¡C¸g¹L¤F¤Q´X¦~¡Aº¥º¥²£¥Í¤F«á¿ò¯g¡A¨Ò¦p¤[¯¸Áv³¡»Äµh¡B¥k¸}½ï±`ÁôÁô°µµh¡A¤Ñ®ð¤£¨Î®É¯S§OÄY«¡B¸y³¡§¤¤[¤F©ö»Äµh¡B¯ÝµÄ¦³®É·|¦³´eµh¡Aµh°_¨Ó§Ï©»¤ßªÈµ²°_¨Óªº·Pı¡C»Äµh¤¤Â媺³B²z¤èªk´N¬O°w¨b©M¼ö¼Åµh³B¡A¦èÂå¤j¦h¥Î¤îµh¾¯©Î¦Ù¦×ÃP¦¢¾¯¥H¤Î«ØÄ³´_«Ø¡A»ÄµhÁöµM§xÂZ¡A¦ý¹ï¥Í©R¤]¨S¤°«Â¯Ù¡A¤]´N»P¤§©M¥¦@³B¡C¦ý¯ÝµÄ´eµh´N«DÀˬd¤£¥i¡A¦èÂåÀˬd¤ßŦ¤@¤Á¥¿±`¡AÂå¥Í§PÂ_À³¸Ó¬O¯Ý¦Ù©âµh¤Þ°_ªº·Pı¡Aµ¹ÓÃĦY¡A¤]¤£µh¤F¡A¦ý¤@°}¤l´N·|§xÂZ¤@¤U¡C
¦ý¤p§ÌÓ©Ê¡A·Q¬°³o¨Ç§xÂZ§äµª®×¡A¥un¹ï¨Åé¨S¦³«I¤J¦¡ªºªvÀø¤è¦¡¡A·|§â¥¦·í°µ¦Û¤v¨Å骺¹êÅç¨Ó¸Õ¸Õ¬Ý¡C¦]½t»Ú·|±µÄ²¨ì¤F¡yì©lÂI¡z¡A¨ä²z½×ÄAÂФ¤¦èÂå²z½×¡A»¡¯uªº¡A¨ü¹L¬ì¾Ç¹êÅç«ä·Q±Ð¨|ªº¤H¤@¶}©l«ÜÃø±µ¨ü³o¼Ëªº¤@ÓÀøªk¡A¦ý¦]¬°¥¦´N¬O±q¤j¶qªº±wªÌ¨¤WÂk¯Ç¥X¨Óªº¾Þ§@¦¡Àøªk¡A²³æÁ¿¡A°µ°µ¬Ý¡A«Ü§Ö´N¥i¥Hª¾¹D²z½×¹ï¤£¹ï¡A¤p§Ì´N¥ý§â¸£³U©ñªÅ¡A·ÓµÛ¥¦ªº¤èªk¥h¾Þ§@¡A³ºµM¾Þ§@¤F¤§«á¡Aªø¦~¤U¨Ó¨Å骺³o¨Ç§xÂZºCºC®ø¥¢¤F¡A©ÎªÌ°¸¦³µo§@¡A¦ý¤]¥i¥H³z¹L¾Þ§@§â¤£µÎªAªº¯gª¬µ¹½w©M¤U¨Ó¡A¤§«á¡A¤p§Ì¯uªº¸ò³o¨Çªø¦~ªº§xÂZ©M¥¦@³B¤F¡C
¤p§Ìª¾±z¬O¨ü¹L¬ì¾Ç°V½mªº¤H¡A¥O¤½¤l¤S¬O´NŪÂå¬ì¡A±Ë¥¿²Î¦èÂå¡AÂà¥tÃþÀøªk¡A¹ê¦b¬ð¤a¡A¦ý±z¤w°µ¤F¦èÂå¸Ô²ÓªºÀˬd¡A°£¤F¤ß¹q¹Ï©M¥i¯à°Æ¥æ·P¯«¸g¸û®z¥~¡A¨ä¥¦ªº¾¹©x²Õ´¬dµL²§ª¬¡A¡y¦b¥Ø«eªºªvÀø¤è¦¡¤£°µ¥ô¦ó§ïÅܪº±¡ªp¤U¡z¡A¡y¹ï¨Åé¤]¨S¦³¥ô¦óªº«I¤J¦¡ªvÀøªº±¡ªp¤U¡z¡A¥Î¬ì¾Ç¹êÅ窺ºë¯«¨Ó¾Þ§@¤@Ó¥i¯à¥i¥H¤j´T§ïµ½¯gª¬ªºÀøªk¡A¥H±zªº°l¨D·sª¾ªºÓ©Ê¡A¥i¥H¹Á¸Õ¬Ý¬Ý¡C±z¤£¥Î§¹¥þ¬Û«Hì©lÂIªº²z½×¡AY¯gª¬¯uªº¦n¤F¡A±z¤]¥i¥H§â³oÓÀøªkµ¹§Ñ±¼¡A¤p§Ì«ÂI¥u§Æ±æ±zµ¹¦Û¤v©Mµ¹ì©lÂI³oÓÀøªk¤@¦¸¾÷·|¡C
ì©lÂI½t¦Û¤¤Âå®v±i°xº~©Ò³Ð¥ß¡A¥¦ªº²z½×«ÂI¦b¤Hªº°·±d»Ýn¨Å餺¦bÀô¹Ò©M¥~¦bÀô¹Òªº¥¿Å¡A·í¥¢¥h¥¿Å®É¡A¨Åé·|·Q¿ìªk¥h°µ½Õ¾ã¡AÁö¦³·l¶Ë¡A¦ý¤]¥¼¥²¥X²{¯gª¬¡A¦ý·í¤º¥~¦bªº·l¶Ë¤O¶q¤Ó¤j®É¡A¶W¹L¨Å骺½Õ±±¯à¤O¡A¯gª¬´N¶]¥X¤F¡A¤]´N¬O¥X²{¤F¯fµhªº²{¶H¡C³o¨Ç¤º¥~¦bÀô¹Òªº·l¶Ë¡A·|ºCºC¤ÏÀ³¦b¨Å骺©T©wªºì©lÂI¨¤W¡Aº¥º¥¦a§Î¦¨¤Fì©lµhÂI¡A¨ÅéY¦s¦b¤Fì©lµhÂI¡AY¨Å骺Åé¤O¤]°I®z(ºÙ¤§¬°¨Å骺¼ö¯à¤£¨¬¡A¤p§ÌºÙ¤§¬°¥Í©R¤O´î®z)¡A¤@¸I¨ì¤º¥~¦bªº·l¶Ë¦]¯À¥X²{(¨Ò¦p¥Í®ð¡B´d¶Ë¡B¹L³Ò¡B¨ü´H¡B¤£·í¶¼¹µ¥)¡A´N¥i¯àIJµo¯gª¬¥X²{¡C¦b¤¤Âå¡A³Ì±µªñì©lÂI²z½×ªº¬O¡u¶Ë´H½×¡v©M®]«äÂ䪺¡uªü¬O¥Þ¡v¡A¦b¦èÂå³Ì±µªñªº¬O¡utrigger point¡v¡A¦ý¡uªü¬O¥Þ¡v©M¡utrigger point¡v¥u³B²z¯kµh¡A¤£³B²z¯e¯f¡A¦Óì©lÂI¨âªÌ³£³B²z¡C
²³æ¨Ó»¡¡AY¤£¬O«æ©Êªº¥~¶Ë©ÎªÌ¬O²Óµß¯f¬rªº·P¬V¡A¤HÅ骺¤j³¡¤À¯kµh©M¯e¯f³£¬O¨Å饢¥h¤F§¡¿Åª¬ºA©Ò¥X²{ªº²{¶H¡A¦Ó¨Åé¤W¦³¼ÆÓ©T©w¦ì¸mªºì©lÂI¡A³o¨Ç¤£¦Pªºì©lÂI´xºÞ¨Å餣¦P¦ì¸mªº¯e¯f»P¯kµh¡A³B²z¯e¯f©Î¯kµh¬O±Nì©lµhÂI¸g¹L«ö±À»P¼ö¼Åªº¾Þ§@¡A¥i¥H¨ë¿E¨Å骺§K¬Ì¤O©M×Å@¯à¤O¡A¨Ãµ¹¤©¾A·íªº¸É¥R¼ö¯à(¤¤Â媺¹¸É)¡A¨Åé±N¦A«ì´_§¡¿Åªºª¬ºA¡A¯kµh©M¯e¯f´N¦]¦Ó®ø¥¢¡C
±z©Ò»Ýn°µªº¡A«Ü²³æ¡A
¤@¡B¸É¥R¼ö¯à¡A¼W¥[Åé¤O¡C¹B°Ê¡G¨Ò¦p§Ö¨«¡B®ð¥\¡B¥¥Ï¥\³£¦æ¡C¹¸É¡G¨Ò¦p¤Hçx´ö¡BÁ¤´ö¡B¤¤Â媺·Å¼ö©Ê¹ª«¡B¤Ö¦Y´H²D©Ê¹ª«¡C
¤G¡B¼ö¼Å¡CÃħ½¶R¤@Ó§N¼ö¼Å¥Î³U¡A¤jªº¡A¥i¥H¸Ë¤ñ¸û¦h·Å¼ö¶}¤ô¡A¤@¤Ñ¨â¦¸¼ö¼Å±zªºì©lµhÂI¡AI³¡ªºì©lµhÂI¥i¥H¨Ï¥Î´¡¹qªº¼ö¼Å¹Ô¡A¦bì©lÂI«ö±À¤§«á¦bì©lÂI¦ì¸m¼ö¼Å¡A·Å«×¥H·Å·xµÎ¾A¬°ì«h¡C
¤T¡B¾Ç·|ì©lÂIªº¦ì¸m¤Î«ö±Àªº¤èªk¡C³oÂI¥i¥H¤Wì©lÂIªº©x¤èºô¯¸¡AùØÀY¦³±Ð¾Çªº¼v¤ù¡A±z¥i¥H¥ý±qÀY³¡ì©lÂI©M¤WI³¡ì©lÂI¾Ç°_¡A¨ä¥¦ªº²z½×©M¨ä¥¦ªº³¡¦ì¦³®É¶¡¦AºCºC¬Ý¡C
±zªº¯gª¬¥Dn¦bÀY³¡©M¯Ý³¡¡B¤ßŦ¡BG¡AÀY³¡¥ÑÀY³¡ì©lÂI´xºÞ¡A¯Ý³¡¡B¤ßŦ¡BG¥Ñ¤WI³¡ì©lÂI´xºÞ¡CÀY³¡ì©lÂI¥Dn¬O¨âÓ¦Õ¦·«á±¤U½t¨âÓ°©ÀY¥æ±µ³B¡A±i¤j¼L¤Ú®É¡A¦Õ¦·«á±¤U½t¦³¤@Ó¥W¬}³B´N¬OÀY³¡ì©lÂI¡A¤p§Ì´±ªÖ©w¡A±zY§ä¨ì¥¿½Tªº¦ì¸m¡A¥Î¹«ü«ü¸¡©ÎÃö¸`³B«öÀ£¡A¤@©w·|¦³¼@µhªº·Pı¡A¦ý¨º¥u¬O¥Ö¦×ªºµh¡A¤â«ü¤@©ñ¶}´N°±¤F¡A«Ü¹³¬O¤â«üÀY³QªùÀ£¨ì©ÎªÌ¤â«üÀY³QÅKºlÂñ¨ìªº·Pı¡A¯gª¬¶VÄY«©Îµo§@ªºÀW²v¶V°ªªº¤H¡A«öÀ£ì©lµhÂI·Pı´N¶Vµh¡A¦ý½Ð±z©ñ¤ß¡Aì©lÂI¦b¸Ñå¾Ç¤W³£¬O°©ÀY®ÇÃ䪺²ÓÁ_©ÎªÌ¦Ù¦×¸s¡A¨S¦³«nªº¯«¸g¦åºÞ³q¹L¡A³oÂI±z¥i¥H½Ð¥O¤½¤l°µ½T»{¡C
«öÀ£n½w¡A¥H¦Û¤v¯à©Ó¨ü¦ý¤S¥²¶·¦³¨Çµh¬°ì«h¡A¦Bá¤T¤Ø«D¤@¤é¤§´H¡A±z¥Ø«eªºì©lµhÂIªºª¬ºA¤£¬Oµuµu´X¤Ñ§Î¦¨ªº¡A¦]¦¹¥²¶·ºCºC¨Ó¡A¨C¤Ñ«öÀ£¨â¦¸¡A«ö«á¼ö¼Åì©lµhÂI¡A§â¼@µhªºì©lµhÂIºCºC«ö¼¯¦¨¤£¤Óµhªºì©lÂI¡A¦b³oÓ¹Lµ{¤¤¡A±zªº¯gª¬©M¤£µÎªAªºÀW²v·|ºCºC°§C¡A±z쥻ªºªvÀø©M¶E
¡u¤@ÁϽk¶îªº24¤p®É¤ß¹q¹Ï¡v¡A¤ß¸õ´å°Ê©ó41¦Ü160¤U........¯uªº«Ü©_©Ç
¦p¶]¨B¤ß¹q¹Ï¡]Treadmill test ¡^70%~80%ªº¥i«H«×¤£¦æ
³Ì«áÁÙ¥i¦Ò¼{64¤ÁCT«aª¬°Ê¯ßÀˬd¦³90%ªº¥i«H«×
¯¬ºÖ±z¦¤é±d´_
±zªº¯gª¬«Ü¹³®£·W¯g,®e©ö¦b¶}¨®®Éµo§@,¥i¥H¸ß°Ý¤@¤UÂå¥Í
¤p§Ì©ó15¦~«e¤]¦³ÄY«¤ß«ß¤£¾ã °µ¤F¤@°ïÀˬd¤]¬d¤£¥Xì¦]
¬O¦Y§¹¦P¨Æ³ß°s«á¹j¤éµo§@,·íªìÂå¥Í¶}ÃÄ(¦WºÙ:XÆQ»ÄX)§Ñ°O¤F
¦Y¤F§óºG,³s¨«¸ô³£µL¤O,¤W¯Z¯Ý¤fÁÙn¶K¦b®à½t¤u§@,¯uªº«ÜµhW
«á¨Ó´«Âå¥Í «ØÄ³§Ú´î»´¥ÎÃÄ,¥»¤H«Ü¤Ö³Ü©@°Ø «ùÄò¥ÎÃĬù¤@¦~
º¥º¥¦n¤F ²{¦b¨C¤é³£³ÜªM®³ÅK´£¯«
ªñ¦~ÃhºÃ¬O³Ü³ß°s¹ª«¤¤¬r¤Þ°_¥B¦Y¤F¹L²rªºÃħó¶Ë¤ßŦ~
¯uªºn¹ï¯g¤UÃÄ §_«h§óºG ¨Ñ±z°Ñ¦Ò.
¯¬ºÖ ²q·Q¤j¦¤é±d´_
º¥ý,¤§«e¦p¦³¹ï±z«_¥Ç¤§³B,¦b³o¸Ì¸ò±z½ßÓ¤£¬O.
±z¸Ó°µªºÀˬd´X¥G³£°µ¤F,°£¤F¤ß¹q¹Ï¦³²§¼Ë¤§¥~,¸£³¡MRIÀ³¥i¥H±Æ°£¸£³¡¸~½F,¸¡³¡¶WµªiÀ³¥iªì¨B±Æ°£¤@¨Ç±`ªø¦b¸¡µÄªº¤º¤Àªc¯«¸g½F,©â¦åÀˬd¤]¥i¥HÂç²M¤@¨Ç¤º¤Àªc¥¢½Õªº°ÝÃD,»{¦Pcliff¤j¤ßŦ¤è±n¦A¶i¤@¨B½T»{,¬Ý¬Ý¤ß«ß¤£¾ã¬O¦óºØ«¬ºA.
¦pªG¤ß¹q¹Ï¬O¤@°}¤@°}ªºÄu©Ê¤ß·i¹L³t,¦pªG³£¨S¸I¯ù.©@°Ø.µÒ.°s,¨º¯uªº«Ü¦³¥i¯à¬O¸ò¦Û«ß¯«¸g¥¢½Õ¦³Ãö«Y.
³oºØ±¡§Î±`±`¬O¤ß¸Ì¦³¤@Óµ²¨S¦³¸Ñ¶}(§Ú¨S¦³«_¥Ç¤§·N,¥u¬O´£¨Ñ¥i¯à©Ê),
³oÓµ²±`·|²o°Ê¤Hªº±¡ºü,±¡ºü´N·|²o°Ê¦Û«ß¯«¸g,³y¦¨¦h¼Ë©Êªº¯gª¬.
¦pªG¦³ªº¸Ü,½Ð¹Á¸Õ¥h§ä´M¨Ã±¹ï³oÓµ²,¦³¾÷·|¸Ñ¶}´N§V¤O¸Ñ,¨S¾÷·|¸Ñ¶}´NÂàÅܤ߹ҹÁ¸Õ©ñ¤U,«e´£¬On±¹ï¥L,³o«Ü«n.
¸Ñ¶}©Î©ñ¤U¤§«á,¬Û«H¤ß±¡©Î¯gª¬±N·|¦³«Ü¤j§ïµ½.§Æ±æ¦³À°¨ì±z,¤]ÁÂÁ±z¤§«eªº«ü±Ð.
§Ú¤]´¿¦³¹L¡¨¦å©¹¸£³¡½Ä¡¨ªº·Pı, ·í®É¤]ÃhºÃ¬O§_n¤¤·. «á¨Ó©M¤@¦ì²¤À´¤¤Â媺ªB¤Í´£¤Î, «ØÄ³§Ú¦pªG¦A¹J¨ì³oºØ±¡§Î, ¸Õ±N¤â«üÂW¯}©ñ¦å, ¥LÁÙ¯d¤F©ñ¦å¤ùµ¹§Ú. «á¨Ó§Ú¤S¸I¨ì³oª¬ªp, ¦ý¤]¤£ª¾nÂW¨º«ü, ´N°®¯Ü±q¤¤«üÂW°_(¦³¥ý¥Î°sºëÀ¿«ø¤â«üÀY®ø¬r), ³°ÄòÂW¤F´X«ü±N¦åÀ½¥X¨Ó. ¬O¦³®ÄªG, ºCºC½w¸Ñ. Â_Â_ÄòÄò§Ú¥Î¹L³o¤èªk´X¦¸, ³£¦h¤Ö¹ï·í¤U¦³½w¸Ñªº¥\¯à. ³o¤w¬O¦h¦~«eªº¨Æ¤F. ³o¬OÓ¤H¸gÅç, «D´£¨ÑÂåÀø°Ñ¦Ò.
¤£ª¾±z·ÓªºÀYÀV³¡MRI¬O§_·Ó¨ìÀV´Õ? ¦³¨S¦³¯«¸gÀ£¢ªº²{¶H? ¤§©Ò¥H³o»ò°Ý¬O¦]¬°±zªºªì©l¯gª¬¡¨·|¯Ý´e ¤ß«ß¤£¾ã §l¤£¨ìªÅ®ð ¸£³¡·|©âµh ·w¯t¡¨µ¥©M§Ú¤jô³¡¤À¬ÛÃþ¦ü, ¥L¶´X°éÀˬd¥X¬OÀV´ÕÀ£¢¯«¸gÃa¦º¡K ÃhºÃ³o¬O¦], ³y¦¨ºØºØ¯gª¬¬OªG. ÁöµMÂå¥Í·í®Én¨D¥L¥ß§Y¶}¤M, ¦Ò¶q¨ì¥i¯àªº«á¿ò¯g, ¨S¨º»ò°µ¡K ¥Ø«eÁÙ¦b´_°·, ¦ý¤w³vº¥±d´_, ¯u¬O¸U©¯! ³o¤¤¶¡¹Lµ{«D¤T¨¥¨â»y¥i³¯z¡K
ˬO¥Lªº¹Lµ{¤¤¦³¨â¼Ëª«²zªvÀøªº¾÷¾¹À°¤F«Ü¤jªº¦£, ¤@¬OÂåÀø¯Åªº»·¬õ¥~½u¾÷, ¥Lª½±µ·Ó¤ßŦ¤ÎªÍŦ, ¹ï¯Ý´e¤Î©I§l¦³À°§U., ¥t¤@¬O3¸U¥ñ¯Sªº¤é¥»¹q¦ìªvÀø¾¹. ¶È´£¨Ñ±z°Ñ¦Ò, ±z¥i¥H¦Û¦æ¤Wºô·j´M¬ÛÃö¸ê®Æ¶i£¸¨B¤F¸Ñ.
¯¬±z¦¤é±d´_ !
1.¤G¦y䲿««¡G¥i¬O¤ßŦ¶Wµªi»¡¬O¥¿±`¡C
2.G¹¹D°f¬y¡GÁö°µ¹LGÃè¡A¦ýG¹¹D°f¬y¬O°ÊºA©Êªº¯gª¬¡A°£«D¤w»G»k¹¹D³y¦¨¹¹D¼ìºÅ¡A§_«h¦³¥i¯à°µ¥X¨Óªºµ²ªG¬O³±©Ê¡F¦ý¸Ü»¡¦^¨Ó¡A¬JµM¬O»´·L°f¬y¡AÀ³¸Ó¤]ÁÙ¤£¦Ü©ó³y¦¨¨º»ò¦hªº¯gª¬¤~¹ï¡C
3.¤ß«ß¤£¾ã¡G¨ºÓ¥iºÃªº¡u¤@ÁϽk¶îªº24¤p®É¤ß¹q¹Ï¡v¡A¤ß¸õ´å°Ê©ó41¦Ü160¤U¡K¡A³o¶µ²§±`ȱo¦A°l¬d¤U¥h¡C·íµM¤´¦³¥i¯à¤ß«ß¤£¾ã¬Oµ²ªG¡]¯gª¬¡^¡A¤£¬O¯f¦]¡C¥t¥~¡A¦³¨S¦³¤ß¦Ù¯Ê®ñ¡A¦ó¤£¦w±Æ¶]¨B¤ß¹q¹Ï¡]Treadmill test ¡^«Kª¾¡H
4.¸~½FÀ£¢¤¤¼Ï¯«¸g¡A³o¤@ÂI§Ú»¡¤£²M·¡¡A§ä¯«¸g¤º¬ìÂå®vÀ°±z¬d¤@¬d¡C
5.³Ì«á¡A¸U¯ë¬Ò¤£¬O¡A´Nn¦Ò¼{¦Û«ß¯«¸g¥¢½Õ¡A³oÓ¥i¯à©Ê·íµM¦³¡A¥u¬On©ñ¦b³Ì«á¡A¥H§K©µ»~¯f±¡¡C
ÁÙ¦³¡A½m®ð¥\µL½×°Ê¥\¡]¤Ó·¥¡B¤ÖªL¡BªL·s¡B¦Ûµo¥\¡B¦U®a®ð¥\¡B·ìÏÉ¡B¥¥Ï¥\¡B¥~¤¦¥\¡K¡^¡A©Î¬OÀR¥\¡]¥´§¤¡K¡^¡A¨ä¹ê³£¬O®í³~¦PÂk¡A¥u°Ý½m¥\ªº¤H¤@¥y¸Ü¡A±z¦³¨S¦³¶i¤J¡u®ð¥\ºA¡v¡H¦pªG¨S¦³ªº¸Ü¡A®{¦³©Û¦¡¦ÓµL®ð·P¡A¥ú¦³·N©À«oµL®ðªº¹B¦æ¡A¸ò°µÅé¾ÞµL²§¡C
®ð¥\ºA¤¶©óºÎ¯vºA»P²M¿ôºA¤§¶¡¡A¦UÓª¬ºA·|§e²{¤£¦P«¬ºAªº¸£ªi¡C
ºÎ¯vºAªº¸£ªi¬O£c»P£_ªi¡FÀW²v¤p©ó7¦¸/¬í¡C
®ð¥\ºAªº¸£ªi¬O£\ªi¡FÀW²v8~13¦¸/¬í¡C
²M¿ôºAªº¸£ªi¬O£]ªi¡FÀW²v14~29¦¸/¬í¡C
©Ò¥H¦b®ð¥\ºAªºª¬ªp¤U¡A¨¤ß¬O³B©ó»´ÃP¡B´r§Ö¡BÃP¡BÀR¡B¦ÛµM¡A¹ï©ó½Õ¸`¦Û«ß¯«¸g¡AÓ¤H¸gÅçı±o¦³©ÒÀ°§U¡Aµ¹±z°Ñ¦Ò¡C
http://www.chikung.org.tw/txt/paper/p15.htm
ÀR§¤½Õ®§¹ï¦Û«ß¯«¸g¬¡©Êªº®ÄÀ³
§@ªÌ¡þ³¢¥¿¨å ¥x¥_ºaÁ`©I§lªvÀø¬ì
¡@¡@¡@³¯°ª´¡@¶§©ú¤j¾ÇÁ{§ÉÂå¾Ç¬ã¨s©Ò
©Î³\¤p§Ì¸Ó³¯z¯f±¡ Åý±z°Ñ¦Ò
¤µ¦~¤¸¤ë ¤p§Ì¶}¨®®É ¬ðı¦å©¹¸£³¡½Ä ¦n¹³§Ö¤¤·ªº·Pı
²Ä¤G¦¸ ³oºØ·Pı§óÄY« ¤£±o¤£°±¨®¥ð®§¥b¤p®É ¤§«á¹ï¶}¨®´N¦³À£¤O¤F
±q¦¹®i¶}¬ÝÂ媺¹Lµ{
è¶}©l ·|¯Ý´e ¤ß«ß¤£¾ã §l¤£¨ìªÅ®ð ¸£³¡·|©âµh ·w¯t ©Ò¥H«æ¶E¦n´X¦¸
¸g«æ¶EÂå®vÂश¬Ý ¤ßŦ¤º¬ì °µ¤F24¤p®É¤ß¹q¹Ï ¤ßŦ¶Wµªi
24¤p®É¤ß¹q¹Ï¬O¤@ÁϽk¶î ¤ß²v¨C¤ÀÄÁ¦b41 ~ 160¶¡¸õ°Ê ¤ßŦ¶Wµªi«hµL²§¼Ë
Âå¥Í¶}¤ß«ß¤£¾ã©M§ÜµJ¼{ªºÃı±¨î
¤S¦]¸£³¡°ÝÃD ¬Ý¤F¯«¸g¤º¬ì ¦Û¶O°µ°·ÀË ¥]§t ÀYÀV³¡MRI ÀV°Ê¯ß¶Wµªi ÁÙ¦³¦å²G±`³WÀˬd ¸¡³¡¶Wµªiµ¥
¥u¦³Áx©T¾J ©M¨â¶µ¸~½F«ü¼Ð(CEA, CA-199)¤£¦X¥¿±`È ¾l§¡¥¿±`
°·ÀË®aÂå¬ì¸ò§Ú¸ÑÄÀ»¡ÁÙ¦n ¦ý§Ú¦Û¤v¤S¶]¥h¦å²G¸~½F¬ì¿Ô¸ß
Âå®v»¡¨âÓȰ¾°ª¦³«Ü¦hì¦] °²¦p¾á¤ß «ØÄ³¥h·ÓPET/CT
µ²ªG¬OªÍ³¡¦³¤@³B«GÂI §PŪÂå®v¥s§Ú¥h¯ÝµÄ¤º¬ì°lÂÜ ¤S¦Û¶O©ç¤F§C¾¯¶q¯Ý³¡CT(¸Ó«GÂI¥i¯à¬O¶t¤Æ)
§éÄˤF´XÓ¤ë §Ú¤G©j§i¶D§Ú ¦o¦h¦~«e¤]¤ß«ß¤£¾ã ì¦]¬OG¹¹D°f¬y©Ò¤Þ°_
¤p§Ì¦³¤@¬q®É¶¡¤]G¹¹D°f¬yÄY« ¤S·Ó¤F¸zGÃè ¤]¥¿±`
¯u´o¤H ¦Y¤ß«ß¤£¾ã©M§ÜµJ¼{ªºÃÄ ¤w¦n´XÓ¤ë
¦ý¦³¦¸§Ö¨«¤§«á(¥¼¥Í¯f¤§«e ¨C¤Ñ³£ºC¶]30¤ÀÄÁ) «o¯Ý´eÄY« ¤ß²v½w©M³t«×¶WºC ¤@¤p®É«á¤~©M½w
§Ú¤S´«¤F§O®aÂå°|ªº¤ßŦ¤º¬ìÂå®v ¨º¤Ñ·f¤õ¨®´N·Pı¤£µÎªA(´«Àô¹Ò·|ıÀY·w²§¼Ë )
¬Ý§¹¤ß¹q¹Ï Âå®v«o»¡§Ú¦³¤ß¦Ù±ð¶ëªººÃ¼{ (¦ý·í®É§Ú¨S¦³¤ß¦Ù±ð¶ëªº¨å«¬¯gª¬ )
¥s§Ú¥h«æ¶E ÁÙ¤£ã§Ú¦Û¤v¨«¸ô n§¤½ü´È
»¡¤]©_©Ç §¤¤W½ü´È §Ú¤Ó¤Ó±À§Ú¨S¦h»· §Ú¬ðµM·Pı·¥«×ªº¤£µÎªA Á٩ǧڤӤӫç»ò±À¨º»òºC
¨ì¤F«æ¶E³B §Ú«_§N¦½ «æ³Ý §l¤£¨ìªÅ®ð
Âå®vµ¹§Ú¦Þ¤U§t¤ù À¹®ñ®ð¸n ©â¦åÀˬd ©ç¯Ý³¡X¥ú
¬ù¹L¤F5¤ÀÄÁ Âå®v°Ý§Ú¦³¨S¦³¤ñ¸ûµÎªA §Ú»¡¨S¦³
«á¨Ó¥´ÂIºw ¤H´N¶}©l½w©M Àˬdµ²ªG¤]¥¿±` ¤U¤È·Ó¤ßŦ¶Wµªi¤]µL²§¼Ë
¦ý¬Oªù¶EÂå®v«on§Ú¦í°|Àˬd Àˬd§¹¤]ÁÙ¦n
·í±ßÂå®v¨Ó§Ú¯f©Ð ¸ò§Úªø½Í¬ù¤@¤p®É »¡§ÚÀˬdµ²ªG ¤£À³¦³³o¼Ëªº¯fªp²£¥Í
©ó¬O¥LÁÙ¬O¶}¤F¦P¼ËªºÃĵ¹§Ú ¥~¥[ªü¥q¤ÇÆF(100mg)
¤é¤l¤]´N³o¼ËÄ~Äò¹L ¦³¤@¤Ñ§Ú¤Ó¤Óªºªí©f´B¨Ó¬Ý§Ú©¨¤÷ ½Í¤Î¥L¤]¤ß«ß¤£¾ãªº¾ãÓÂåÀø¹Lµ{
¥L»¡¥L¬O¦Û«ß¯«¸g¥¢½Õ ¥s§Ú¥h¬Ý¹Å¸qªº¬Yºë¯«¬ìÂå®v¸Õ¸Õ¬Ý(¥L¦í®ç¶é «o¨Ó¹Å¸q¬Ý¯f)
§Ú¥´¹q¸Ü¥h¹w¬ù ¤@Ó¦h¤ë¤~¬Ý¨ìÂå®v
¥¦¥Î»ö¾¹´ú¸Õ »¡§Ú¬O°Æ¥æ·P¯«¸g¤Ó®z ´N¶}Ãĵ¹§Ú ª½¨ì²{¦bÁÙ¦bªvÀø
²{¦bªº§Ú ¦¤W¦Y¿P³Á¤ù ¤@ªM½ªG¥Ä ¦b¤½¶é²`©I§l100¦¸ §Ö¨«¤@¤p®É ¥¥Ï¥\1 ¦¸
¤U¤È§Ö¨«¤@¤p®É ¥¥Ï¥\1 ¦¸
¥u¦b±ß¤W¬Ý²³¤j¤jªº¤j¤å¤Î¸ê®Æ
³o´N¬O¤p§Ì²{¦b¤j²¤ªº±¡ªp
§Úª¾¹D¤ß±¡¼ÖÆ[«Ü«n §Ú±`´£¿ô¦Û¤vn¯º¤f±`¶} ¯uªº¤ß±¡´N¶}®Ô°_¨Ó
½Ð±z¤]¤£¥²«æ ¦³ªÅ¦A¼g«K¥i ½Ð§O¼õ©]¼g³á!
ÁÂÁ±z! ·P®¦!
·PÁ¾ɤޡA¶WÆg¡I
²q·Q¤j¡A
¯¬¦¤é±d´_¡I
«z¡I¦n´Î³á¡I¯u¬O¤Ó·PÁ±z¤F¡I
±zÀ³¸Ó§ï¦W¥sJACKªº¡AHaHa!
±z£¸©w¬O¤p§Ìªº¸t½Ï¦Ñ¤½¤½...
ÁÂÁÂJM¤j¡IªÈ·P¤ß£°^_^¡ã
¯E¤ÍÌ
³o¸Ì¦³«Ü¦«Ü¦¥H«e¤j®a§V¤O¹Lªº¨¬¸ñ
·í®É¯uªº¬O£¸¸s¤H¦bºN¶H
¦ý¤j®aÃh©êµÛ¤@¥÷¹Ú·Q¡B¼ö±¡...
°²¤é¦³ªÅ¤£§«¨Ó³}³}
¤]§Æ±æ¦¹½gªº¯B¥XÅý²q·Q¤j°·±d§ó°·±d
¯¬ºÖ²q·Q¤j
ÁÂÁÂJM¤j
·PÁ§A̪º¤À¨É»P»¡©ú
²Î¾ã¤j®a¤ÀªRªº¸ê®Æ¡A¤]´N¬O»¡
1.¦b³Ì«á¤@¦ì¯f¤H¥´§¹²Ä9°w¤§«e¡A·í¤H¼Æ¹F¨ì¸Ó´Á¤¤¤ÀªR®É¡AÁÙ¬O¥²»Ý¶i¦æ
¦ý³Ì«á¤@¦ì¯f¤H¥´§¹9°w«á¡A§Y¨Ï¨ì¹F´Á¤¤¤ÀªR¤H¼Æ¡A¤]¤£·|¶i¦æ¡A´Nµ¥¸Ñª¼¤F
2.±Û«a¤j¤§«e´¿´£¹L¤@Ó«ÂI¡G
¯E¹©¤½¥q¦b¥Ó½Ð¤WÂd®É¡A´¿¥D°Ê»¡©ú¤£·|´Á¤¤¤ÀªR¡A³o¬OÓ¦n®ø®§
3.¸g¾úªF¬v¨Æ¥ó«á¡A§Ú·Q¤j®a³£©È¡u¥N¤u¡v¡A©Ò¥H§Ú̧O«æ¡A¶¶«Kµ¥¼í¶®
4.¨C¤Ñªº³Ì«á¤@µ§¥æ©öÁÙÆZ¦³½ìªº¡A¤j®a¥i¥HªY½à¤@°}¤l
5.´Á«Ýªk»¡·|¡A¦ý¤ß¤¤¤£«æµÛ¸Ñª¼¡A¥u¬O¬°³o¨Ç¯f±w¦³ÂI±{±¤
6.²{¦b¶}©l¡A¨C¹L¤@¤Ñ¡B¤@Ó¤ë´N§â¯E¹©»P¯E¤Í©¹¦¨¥\±Àªñ
7.¦]¬°´o¤HªºIPO,«o¥i¯à³y¦¨¯E¹©¤WÂd«áªºÂêªÑ
¤j®a......«ç»ò¥i¥H¤£´¤ºò©O
¦pªG¦~©³ªÑ»ù¨ì¤F6-8¦Ê¡A¦³¤H¦b½|§A̳o¨Ç¶R¦b3¡B4¦Êªº¯E¤Í
³o®É¡A´«§A̲zª½®ð§§ªº§i¶D¥LÌ¡u§A̪¾¹D§Ú̬O«ç»ò¼õ¹L¨Óªº¶Ü¡H¡v
©Ò¥H
¤@°_
¥[ªo
©ó2014-7-21§¹¦¨342¦ì¦¬®×, °²³]²Ä342¦ì¨ü¸ÕªÌ©ó2014-7-22¬I¥´²Ä¤@°w, ¬I¥´²Ä8°wªº²Ä25¶g¬°2015-1-6, ¬I¥´²Ä9°wªº²Ä37¶g¬°2015-3-31.
OBI-822/821¤G/¤T´ÁÂಾ©Ê¨ÅÀùÁ{§É¸ÕÅç, ³]©w¤G¶µ«ü¼Ð(endpoint)n¹F¦¨,
1. Primary endpoint: PFS±q6Ӥ봣°ª¨ì9Ó¤ë, 2. Second endpoint: OS±q18Ӥ봣°ª¨ì27Ó¤ë.
ºâ¨ì¤µ¤Ñ, PFS¦¤w¶W¹L9Ó¤ë, ¦ý¬OOSÁÙ¨S¹F¨ì27Ó¤ë, ©Ò¥H2015¦~Q3©ÎQ4¸Ñª¼, ¤£¥uPFS¶W¼Ð, OS¤]¯à¹F¼Ð.
§ó«nªº¥Ø¼Ð¬OÅýPFS¶W¶V¥Ø«e©Ò¦³ªº¨ÅÀùÃÄ, ¹F¨ì¥@¬É²Ä¤@ªº©_ÂÝ, ¬°¥xÆW«~µP¤Î¥xÆWªºÀù¯g·sÃĬãµo¥ß¤U¼Ð¬ñ.
¨ì¦~©³, ¼í¶®Ãļt¥i¯à§¹¦¨Åç¼t, ¥i¥H¶q²£OBI-822/821©M833/821.
¶}·|®É¶¡¡G¤E¤Q¤E¦~¤Q¤@¤ë¤@¤é¤U¤È¤G®É¥¿ ¡y¥»¸ÕÅç©ó 176 ¨Æ¥óµo¥Í·|°õ¦æ¤@¦¸´Á¶¡¤ÀªR¡z¡A¨ä©Ò¹ïÀ³¤§ÅãµÛ¤ô·Ç¤§±Àºâ¤è¦¡À³¥H 176 °£¥H 284 ¦Ó«D 176 °£¥H 342¨Ópºâ¤§¡C¤p§Ì¥H¬°»O¥_ºa¥ÁÁ`Âå°|¬O¸ÕÅçÂå°|¡A·|¤£Â_¦¬¨ì·sªº¸ÕÅçp¹º®Ñª©¥»v1.v2.v3....«ö·Óp¹º®Ñ«ü¥Ü°õ¦æ¡A¦pªG¤j®a¤£¬Û«H¸ÕÅçp¹º®Ñ¥Õ¯È¶Â¦r¡A§Ú¤]¤£ª¾¹D¤j®an¬Û«H¤°»ò¡H
2.§Ú¦³po¹L¨ÌLachin¤½¦¡¡A¥i¥H¤Whttp://www.cct.cuhk.edu.hk/stat/survival/Lachin1981.htm#2¡C
3.¦A¡Eªþ¤W¶§©ú¤j¾Ç³¯®a¼zºÓ¤h½×¤å¡y±´°Q¨ÅÀùÁ{§É¸ÕÅ礧´Á¤¤¤ÀªR¡zhttp://140.113.39.130/cgi-bin/gs32/ymgsweb.cgi/login?o=dymcdr&s=id=%22GYF225229545%22.&searchmode=basic ùر¦³¨Ç¾ú¦~¨Ó¨ÅÀùÁ{§É¸ÕÅçÁ{§É¤H¼Æ¤Î¨ä¤¤¤ÀªR¤H¼Æ¸ê®Æ¡A¬Ý¬Ý¬O¤£¬O¡yèè¦n¡z³£¬OÁ{§É¤H¼Æ¤@¥b¡A¦pªG¤£¬O´N¤£¥²¦Aª§½×¬O176¡H171¡H142¤H¡H§Ú»{¬°176¥u¬Oè¦n±µªñ342¤Hªº¤@¥b171¤H¡A±i¸³¤è«K¸ÑÄÀ´N»¡´Á¤¤¤ÀªR¤H¼Æ¬O¡y¦¬®×¡z¤H¼Æªº¤@¥b¡F¨º¤S¦³¤H·Q»¡À³¸Ó¬O¦³®Ä²Îp¤H¼Æ284¤Hªº¤@¥b142¤H¡C§Ú¥u·Q»¡³o¤@¤Á³£©M¡y¤@¥b¡zµLÃö¡A¸ÕÅç©Ò»Ýªº¯f±w¼Æ¥Ø©M´Á¤¤¤ÀªRµo¥Í¨Æ¥ó¼Æ¬O¤½¥q¦b³]p¸ÕÅç®É¹w¦ô¤ñ쥻¼Ð·Ç¤Æ¾ÇªvÀøªº·ÀI²v¦A¥[¤W¤@¨Ç¼Æ¦rºâ¥X¨Óªº¡A¦b³]pÁ{§É¸ÕÅç®É´N©w¦n¤F«áÄò·|¨Ì¸ÕÅç¶i¦æ¶¶§Q»P§_¶i¦æ½Õ¾ã¡A¤p§Ì¨ÃµLp¹º®Ñ¦ýYµL¼W¦¬Á{§É¤H¼Æ«h´Á¤¤¤ÀªR¤H¼ÆÀ³¤£·|½Õ¾ã¡C
´N¹³Faith¤j»¡ªº¸Ó¦³®Ä¡B¸Ó´_µoªº³£®t¤£¦h¤F¤UÓ¤ë¬Æ¦Ü3¤ë¶}©l´_µo¤H¼Æ·|ÁÍéw¡AÂ÷´Á¤¤¤ÀªR©Î¸Ñª¼ªº¤é¤l¶V¨Ó¶Vªñ¡A§Ú·Q¦b¨S¦³§ó§ï¸ÕÅçp¹ºªº«e´£¤U¡A¤j®a´N¥H»O¥_ºa¥ÁÁ`Âå°|²Ä¤@¤HÅé¸ÕÅç©eû·|²Ä 10 ¦¸·|ij¬ö¿ý ¤½§iª©ªº176¤H¬°ª©¥»°µ¦UºØ±À½×¡A§_«hÅܼƤS¦h¤@Ó¤j®an¤À2¡B3ºØ¼Æ¦r°µ°²³]¡A²¦³º´Á¤¤¤ÀªRÁÙ¬O¦³¥i¯àµo¥Í¤£ª¾¦U¦ì¤j¤j¥H¬°©O¡HY¦³§ó¦n·QªkÅwªï¤À¨É¡AÁÂÁ¡C
¤W¤@½g¿ù¦r
¬O"ÁÂ"(äÁÂ)
¤é¤l¤S©¹«e±À¤F¤@Ó¤ë
¤@¤ëªºµ²§ô¥Nªí³Ì«á¤@§åªº¦¬®×¯f¤H¤w¸g¾ú6Ó¤ë8°w
¸Ó¦³®Ä¡B¸Ó´_µoªº³£®t¤£¦h¤F
¤UÓ¤ë¬Æ¦Ü3¤ë¶}©l´_µo¤H¼Æ·|ÁÍéw
³Ìªñ¤@ª½«ä¦Ò¤@Ó°ÝÃD
Ãö©ó´Á¤¤¤ÀªR¡A´Á¤¤¤ÀªR¥Dn¬O¤ÀªRÃĪ«ªº¦w¥þ©Ê
¥H¥Ø«e¨Ó¬Ý¡A¬O¨S¦³´Á¤¤¤ÀªRªº¥²n©Ê¤F
¦ý¬O¸U¤@´_µo¤H¼Æ¹F142©Î176¡]¦³¯E¤Í´£¨ì§õ¤p©j»¡¬O142¡^
À³¸ÓÁÙ¬On´Á¤¤¤ÀªR§a
§Ú¬O°Ñ¦Ò°ò¨È¡A¥¦¤§«e¦¬§¹®×«á¡A¸Ñª¼¤Î³Q¢´Á¤¤¤ÀªR¦P®É¶i¦æ
³oÂI¤£ª¾¤p§Ìªº»{ª¾¬O§_¥¿½T¡H
¦pªG½T¹ê¹F³oÓ¤H¼Æ´Nn³Q¢´Á¤¤¤ÀªR¡A¦Ó¯E¹©¤@ª½¤£»Ý´Á¤¤¤ÀªR
§q«J....,
¥t¥~¡A³ÌªñªºªÑ»ù¤j®a¨Sµo²{¬O¤@ºØÃÀ³N¶Ü¡H
¤W¤£¥h¤]¤U¤£¨Ó¡AÆZ¦³½ìªº
©ñªø½uªº¯E¤ÍÌ¡A§ÚÌ´N¨Óµ¥µ¥¬Ý³o¤@ªin«ç»ò¨«§a
¡]¦pªG¬O¸g¾ú150-170¨º6Ӥ몺¯E¤Í¡A¹ï§A§Ú¦Ó¨¥¡A¤@ÂI³£¤£Ãø¼õ¡A¤£¬O¶Ü¡H¡^
¶R¨ì455¥ª¥k¦Ó¹w³Æ°µªø½uªº¯E¤ÍÌ
±i¸³³£»¡¡G³o¬O¤@¤ä¤¤¼ú¾÷²v«Ü°ªªºªÑ²¼
§AÌ«ç»ò¥i¥H¨S@¤ß¡H¤£½ä½ä¬Ý©O¡H§Ú̳£µ¥ªº¤ñ§A̤[¤F
§A̬ݦü¶R¦b°ªÂI¡A¥i¤]Â÷¦¨¥\¶Vªñ¤£¬O¶Ü
µ¥¨ìªá¨à³£¬ª¤F¡AÀ³¸Ó«üµ¥¸Ñª¼¤é§a¡I«¢«¢
©¡®É¡A§Ú©È§Ú̳£nµ¥¨ìµo§Ý¤F¡I¦]¬°³o±i±m¨é...¤@©wn´¤ºò
¤@°_
¥[ªo
§ë¸ê¬Ò¦³·ÀI¡A¦ý§ë¸ê¤ñ§ë¾÷¦n¤Ó¦h¤F
°w¹ï±zªº¦Ò¶q ¤p§Ì¸Õºâµ²ªG ¦C¦p ªí1
¨âªÌÁ`¥Í¦s¾÷²v¬ï¹L 0.5 ¤ô¥½uªº±¡ªp
¤À§O¬° ³]¸ê®Æ¼Æ¬ù 100 ¤H ´c¤Æ¤H¼Æ 83~86 ¤H ¡Q ³]¸ê®Æ¼Æ¬ù 105 ¤H ´c¤Æ¤H¼Æ¬ù 83 ¤H
ÁöµM¦³ÂI®t§O ¦ý¹ï¦ôºâ ¤¤¦ìPFS ©Î³\¨S¤°»ò®t²§?
¤SY¦Ò¼{¥¢Áp¤H¼Æ( 11¤H ) ¸m«e©M¸m¤¤ªº¸Õºâµ²ªG ¤À§O¦C©ó ªí2 ¤Î ªí3
¤GªÌÁ`¥Í¦s¾÷²v¬ï¹L 0.5 ¤ô¥½uªº±¡ªp
¤À§O¬° ³]¸ê®Æ¼Æ¬ù 90 ¤H ´c¤Æ¤H¼Æ 77 ~ 80 ¤H ¡Q ³]¸ê®Æ¼Æ¬ù 100 ¤H ´c¤Æ¤H¼Æ¬ù 80 ¤H
¥¦Ìªº¤¤¦ìPFS¤]À³³£¤j©ó19Ó¤ë ?
¤p©_¤j ±zªº³Ð·s«ä¦ÒÅÞ¿è¶WÆg Åý¤p§Ì±o¥HÂç²M«Ü¦h 822 ¤¤¦ìPFS pºâ¤W¤£½T©wªº¦a¤è
¥Î³o¼Ë«O¦uªº¦ôp Ó¤H·Pı Áö¤£¤¤À³¤]¤£»·¤F!?
ÕY¥¼¨Ó¦³·s»¡ªk©Î¸ê®Æ §Ú̦A¨Ó½Õ¾ã
ÁÂÁ±zªº«ü¾É!
¸Õºâªí 1
0 228 0 1.00000000 1.00000000
5 228 23 0.89912281 0.89912281
5 200 3 0.98500000 0.88563596
5 192 3 0.98437500 0.87179790
5 184 3 0.98369565 0.85758381
5 176 3 0.98295455 0.84296590
5 168 3 0.98214286 0.82791294
5 160 3 0.98125000 0.81238957
5 152 3 0.98026316 0.79635557
5 144 3 0.97916667 0.77976483
5 136 3 0.97794118 0.76256413
5 128 3 0.97656250 0.74469153
5 120 3 0.97500000 0.72607425
5 112 3 0.97321429 0.70662583
5 104 3 0.97115385 0.68624239
5 96 3 0.96875000 0.66479732
5 88 3 0.96590909 0.64213377
5 80 3 0.96250000 0.61805375
5 72 3 0.95833333 0.59230151
5 64 3 0.95312500 0.56453738
5 56 3 0.94642857 0.53429431
5 48 3 0.93750000 0.50090091
5 40 3 0.92500000 0.46333334
¸Õºâªí 2 ( ¥¢Áp¤H¼Æ11¤H ¸m©ó«e )
0 228 0 1.00000000 1.00000000
16 228 23 0.89912281 0.89912281
5 189 3 0.98412698 0.88485102
5 181 3 0.98342541 0.87018498
5 173 3 0.98265896 0.85509506
5 165 3 0.98181818 0.83954788
5 157 3 0.98089172 0.82350557
5 149 3 0.97986577 0.80692492
5 141 3 0.97872340 0.78975630
5 133 3 0.97744361 0.77194225
5 125 3 0.97600000 0.75341564
5 117 3 0.97435897 0.73409729
5 109 3 0.97247706 0.71389277
5 101 3 0.97029703 0.69268804
5 93 3 0.96774194 0.67034326
5 85 3 0.96470588 0.64668409
5 77 3 0.96103896 0.62148860
5 69 3 0.95652174 0.59446736
5 61 3 0.95081967 0.56523126
5 53 3 0.94339623 0.53323704
5 45 3 0.93333333 0.49768790
5 37 3 0.91891892 0.45733483
5 29 3 0.89655172 0.41002433
¸Õºâªí 3 ( ¥¢Áp¤H¼Æ11¤H ¸m©ó¤¤ )
0 228 0 1.00000000 1.00000000
5 228 23 0.89912281 0.89912281
5 200 3 0.98500000 0.88563596
5 192 3 0.98437500 0.87179790
5 184 3 0.98369565 0.85758381
5 176 3 0.98295455 0.84296590
5 168 3 0.98214286 0.82791294
5 160 3 0.98125000 0.81238957
5 152 3 0.98026316 0.79635557
5 144 3 0.97916667 0.77976483
16 136 3 0.97794118 0.76256413
5 117 3 0.97435897 0.74301120
5 109 3 0.97247706 0.72256135
5 101 3 0.97029703 0.70109914
5 93 3 0.96774194 0.67848303
5 85 3 0.96470588 0.65453657
5 77 3 0.96103896 0.62903515
5 69 3 0.95652174 0.60168580
5 61 3 0.95081967 0.57209469
5 53 3 0.94339623 0.53971197
5 45 3 0.93333333 0.50373117
5 37 3 0.91891892 0.46288811
¤p§Ì·Q¤F·Q¡AÁÙ¬O§â¸Õºâªí¥[¤J¥¢Ápªº¥i¯à¤H¼Æ¦n¤F
ÁöµM¸ÕÅç²ÕÃĦ³®Ä¡A±wªÌÀ³¸Ó¤ñ¸û¤£·|¥D°Ê¥¢Áp
¦ýÁÙ¬O¥[¤J¥¢Áp¤H¼Æ·|Åý¸Õºâªí¤ñ¸û§¹¾ã
´N¥Î5%¤j¬ù11¤H
©Ò¥H˱À100¤H¡A°£¤F2013¦~7¤ë~2014¦~7¤ëªº86¦ì³]¥~¡A
¦A¥[¤W11¦ì¦b¤ñ¸ûµuªº®É¶¡´N¥¢Ápªº³]¤H¼Æ
©Ò¥H˱À100¤H´N·|¸¨¦b2013¦~6¤ë
¥ý¥Î¦³§â´¤ªº°²³]¡Aµø±¡ªp»Ýn¦A°µ½Õ¾ã¡C
¥Ø«e¨ÅÀù¥½´ÁÀøªkªºPFS¬O´XÓ¤ë©O?
ÁÂÁ±z
¤p§Ì¯u¨ØªA±z¡A쥻ÁÙ¾á¤ß¤å¦rªºªí¹F·|µü¤£¹F·N¡I
¦A¤@ÂIÂI¤p¤pªº°Q½×¡A
228 0 1.00000000 1.00000000
0 228 23 0.89912281 0.89912281
5 205 3 0.98536585 0.88596491
5 197 3 0.98477157 0.87247306
5 189 3 0.98412698 0.85862428
5 181 3 0.98342541 0.84439294
5 173 3 0.98265896 0.82975029
±zªº¶¶§Ç¬O¥ý23¤H´c¤Æ¡AµM«á5¦ì³]¡A¦A¨Ó3¦ì´c¤Æ¡F¦A5¦ì³]¡AµM«á3¦ì´c¤Æ¡H
ÁÙ¬O¶¶§Ç¬O¥ý23¤H´c¤Æ¡AµM«á3¦ì´c¤Æ¡A¦A¨Ó5¦ì³]¡F¦A3¦ì´c¤Æ¡AµM«á5¦ì³]¡H
¦pªG¬O«eªÌ¡A¤p§Ìı±o¥H¤Uªººâ¦¡¤ñ¸û¥¿½T¡G
0 228 23 0.89912281 0.89912281
5 200 3 0.98500000 0.88596491 ...¥ý³]5¦ì¡A¦]¦¹·í´Á¤T¦ì´c¤Æ®É¡An at risk=205-5=200
5 192 3 0.98437500 0.87247306
5 184 3 0.98369560 0.85862428
5 176 3 0.98342541 0.84439294
5 168 3 0.98265896 0.82975029
pºâ¾÷§Ú´N¨S¦³¥J²Ó«ö¤F¡C
¡y¤S¥Ñ¤p©_¤jµ¹ªº¦¬®×¶i«× ¥H³]¸ê®Æ¼Æ100 ˱À®É¶¡ ¤j·§¸¨©ó 6 ¤ë©³ (¶Z²{¦b19 Ó¤ë)¡z
³]¸ê®Æ¼Æ100 ˱À¡A2013¦~7¤ë¨ì2014¦~7¤ë¦@¦¬96¤H¡A¦©°£10%¬ù10¤H¦¦´c¤Æ¡A¦]¦¹2013¦~7¤ë¥H«áªº³]¤H¼Æ³Ì¦h¥u¦³86¤H¡An˱À¨ì100¤H¡A¤j·§n±À¨ì2013¦~ªº5¤ë¡A¶Z²{¦b¦³20Ó¤ë¡Cm¤]´N¬O83~86¥X²{¤F¡A¦¹®É³o¦ì±wªÌªº´c¤Æ®É¶¡´N¬OT¡AT·|¤j©ó˱Àªº²Ä100¦ì³]¸ê®Æ¡A¤]´N¬OT·|¤j©ó20Ó¤ë¡A¦ÓT´N¬O¤¤¦ì¼ÆPFS¡A¤]´N¬O¤¤¦ì¼ÆPFS¤j©ó20Ó¤ë¡C
¡y¦ý§Ṳ́§«e¤S°²³]76¤H´c¤Æ¬°¸Ñª¼³]©wªº±ø¥ó ©|¥¼¹F83~86¤H¡z
¦b¦¹¨Ò¤¤¡A¸ÕÅç²Õ¦³83~86¤H´c¤Æ¡A¤~·|¹F¨ì¬ï¹L0.5¤ô¥½u¡A¦pªG¤£¤p¤ß¤Ó¦´¦¶}¡Aµo²{¸ÕÅç²Õ¥u¦³76¤H´c¤Æ¡AKM¨ç¼Æ·|¦Q¦b0.5¤ô¥½u¤§¤W¡A³o®É´NÀª§¼¤F¡An»\°_¨Ó¦A«·sµ¥¨ì¹F¨ì0.5¶Ü¡HÁÙ¬O¥Î³oºØ¹Ï«¬FDA¤]¥i¥H±µ¨ü¶Ü¡H
·PÁ²q·Q¤j±z»P¤p§Ìªº¬ä½R°Q½×¡A¤]¦]¬°³o¨Ç°Q½×¡A¤p§Ì¤~·|§â¦s¬¡¨ç¼Æ°µ³o»ò²`¤Jªº«ä¦Ò¡A§Ú·Q¡A¨ì¦¹¡A¤p§Ì¹ï©ó¦s¬¡¨ç¼Æªº»{ÃÑ»P±z¨S¦³¥ô¦ó®t²§¤F¡C
¤p©_¤j¶WÁo©ú ¯à°÷±Àºt¥X³o®MpºâÅÞ¿è Åý¤HªY¸r
¤p§Ì¬Ý¤F¼Æ¦¸ ¤~²¤²¤Åé·|Ó¤¤ºëÀH(¤£ª¾³o¦¸·|¤£·|¤S¤£À´¸ËÀ´ ¤S»~¸Ñ¤F?!)
¨Ì¤p©_¤j²Ä¤@¨Òªº°²³] ¸Õºâ¦p¤U
¨CÓª½ÄæªºÄæ¦ì¦WºÙ ¥Ñ¥ª¦Ü¥k¤À§O¬° ¡m ³]¸ê®Æ¼Æ ¡n,¡m n at risk §Y n( i ) ¡n,¡m d( i ) ¡n,¡m ¶¥¬q¦s¬¡¾÷²v §Y 1- d( i )/ n( i ) ¡n, ¡m Á`¦s¬¡¾÷²v ¡n
228 0 1.00000000 1.00000000
0 228 23 0.89912281 0.89912281
5 205 3 0.98536585 0.88596491
5 197 3 0.98477157 0.87247306
5 189 3 0.98412698 0.85862428
5 181 3 0.98342541 0.84439294
5 173 3 0.98265896 0.82975029
5 165 3 0.98181818 0.81466392
5 157 3 0.98089172 0.79909709
5 149 3 0.97986577 0.78300789
5 141 3 0.97872340 0.76634815
5 133 3 0.97744361 0.74906210
5 125 3 0.97600000 0.73108461
5 117 3 0.97435897 0.71233885
5 109 3 0.97247706 0.69273319
5 101 3 0.97029703 0.67215696
5 93 3 0.96774194 0.65047448
5 85 3 0.96470588 0.62751655
5 77 3 0.96103896 0.60306786
5 69 3 0.95652174 0.57684752
5 61 3 0.95081967 0.54847797
5 53 3 0.94339623 0.51743204
5 45 3 0.93333333 0.48293657
¥Ñ¦¹·§ºâªí ³]¸ê®Æ¼Æ¤j¬ù100 ´c¤Æ¤H¼Æ¬ù83~86 Á`¦s¬¡¾÷²v·|¬ï¹L0.5
¤S¥Ñ¤p©_¤jµ¹ªº¦¬®×¶i«× ¥H³]¸ê®Æ¼Æ100 ˱À®É¶¡ ¤j·§¸¨©ó 6 ¤ë©³ (¶Z²{¦b19 Ó¤ë)
¦ý§Ṳ́§«e¤S°²³]76¤H´c¤Æ¬°¸Ñª¼³]©wªº±ø¥ó ©|¥¼¹F83~86¤H
¦]¦¹±ÀÂ_ ¤¤¦ìPFS ¤j©ó19Ó¤ë
³oÓ¸ò¹Ç§AÅó±ø±ø¤jªº¦ôºâ¤è¦¡ ¦n¹³¤]«Ü±µªñ
¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
¤]¦A¦¸·PÁ¤p©_¤j ¹Ç§AÅó±ø±ø¤jªº¤À¨É¸Ñ»¡
1.·í¦³³]¸ê®Æ®É¡A¦]¬°dt=0,·|³y¦¨¯AÀI²vH(t)=dt/L(t-1)=0 dtªí¥Ü°Ï¶¡¤º¦º¤`¤H¼Æ¡AL(t-1)ªí¥Ü°Ï¶¡ªì¦s¬¡¤H¼Æ
2.¦]¦¹¦s¬¡²vS(t)=S(t-1)*(1-H(t)) »P¤W¤@°Ï¶¡ºû«ù¤£ÅÜ, ¦ýL(t-1)¦]¬°²¾°£¦¹³]¤H¦Ó´î¤Ö
3.«á¨Ó·í¸Ó²Õ¦³±wªÌ´c¤Æ¡A¥Ñ©óL(t-1)¦AÄ~Äò´î¤Ö¡AH(t)·|¥[³t´î¤Ö(¦³ÂI¹³§â2ªº³¡¤À¤@¦¸¶^¨¬)
¤£ºÞ³]¸ê®Æ¦h¤Ö¡A¤]n¦b1/2(¹êÅç²Õ¤H¼Æ-³]¤H¼Æ)ªþªñ®É¡AK-M·|¬Û¥æ¦b0.5
³oÓ´Nªí¥Ü¤£¥Î¥h¦ôp³]¤H¼Æ¦h¤Ö¡A¥Î¥§¡¦¬®×¤H¦¬®×®É¶¡¨ì¥Ø«e®É¶¡¦@¸g¹L¦h¤Ö®É¶¡·í§@¦s¬¡´Á¬O¥i¥H°µ¬°°Ñ¦Òªº¡A
¤½¥q»¡2013¦~6¤ë¦¬¨ì±Nªñ200¤Hªº¸Ü¡A©Ò¥H²Ä172¤H¬O2013¦~6¤ë«e¦¬¨ìªº¡A
¦Ó¨ì2015¦~1¤ë¤´µM¨S¦³»Ýn´Á¤¤¤ÀªR¡A¨ºÁ`PFS¦Ü¤Ö¬O19Ó¤ë
¦]¬°¹êÅç»P¹ï·Ó²Õ2:1, °²³]¹ï·Ó²ÕPFS=9, ¹êÅç²ÕPFS=X, 2/3 * X + 1/3 * 9 = 19, X=24, ²{¦b¹êÅç²ÕPFS¤w¸g>24
¥Î«Ü²³æªººâªk¡A·íµM·|¦³»~®t¡A¶È¨Ñ°Ñ¦Ò
(¦³¨Ç¯E¤Í¥i¯à·|»{¬°§Ú·Q±o¤Ó²³æ¡A¥i¬O¨Æ¹ê¤W¡A½ÆÂøªºpºâ¤½¦¡©¹©¹¥u¬O¨Ó¦Û¥X³Ìì©lªº¼Æ¦r¡A´N¬O"PFS"
,´N¦n¹³¹]²y±q¤ñÂÄÅK¶ð±¼¤U¨Ó¦]¬°ªÅ®ðªý¤O¥i¥H©¿µø, Gȫܱµªñ«¤O±`¼Æ¡A¦Ð¤ò«h¤£¦æ¡A
¹ï©ó§Ú³oÓ²¤Æ¼Ò«¬¦Ó¨¥¡A¦ý¬O¦pªG¹êÅç²ÕPFS=X, ¹ï·Ó²Õ=9...¨ä¾lªº³]¸ê®Æ¡AÓ§O®t²§·|¦³¡A¦ý¬O¤]·|±µªñ²¤Æ¼Ò«¬)
¨ä¹ê§Úªº·N«ä¤£¬O¤@©w¶W¦ô©Î§C¦ô¡A¦Ó¬OKM¨ç¼Æ°£«D¯uªº¸Ñª¼¡A¤£µM¥Î¦ôºâªº¥u¯à¦ô¤¤¦ì¼ÆPFS¦b¬YÓ½d³ò¡A§Ú©Ò°µªº¦ôºâ¬O¥Î«O¦uªº¤è¦¡¡A¤]´N¬O·|¤j©ó¦h¤Öªº¤è¦¡¡A¹ê»Úªº¼Æ¦r¥i¯à¤ñ§Ú¦ôºâªº¼Æ¦r¨Ó±o¦n¡C
´Nºâª¾¹DÁ`´c¤Æ¤H¼Æ¡A¥B¹ï·Ó²Õªº´c¤Æ¤H¼Æ¤]ª¾¹D¡A¤]´N¬O»¡¸ÕÅç²Õªº´c¤Æ¤H¼Æª¾¹D¤F¡A¦]¬°³]¸ê®Æ»P´c¤Æ¸ê®Æªº±Æ¦C²Õ¦X¦³¬Û·í¦hªº¥i¯à©Ê¡A¦P¼Ë¬O¹F¨ì0.5ªºÁ`¦s¬¡¾÷²v¡A·|¦³¤£¦Pªº²Õ¦X¤è¦¡¨Ó¹F¨ì¡A¤p§Ì¥u¥Î¤F¤@ºØ¥i¯à©Ê¨Ó±À¦ô¡Aºâ¬O¤ñ¸û«O¦uªº±À¦ôªk¡A²{¦b¬Ý¤F±zªº¸Õºâªí¡A¬ðµMÆF¾÷¤@°Ê¡A¦ó¤£É¥Î±zªº¸Õºâªí¨Ó¦ôºâ¤£¦Pªº²Õ¦X¤è¦¡¡A¬Ý¬Ýµ²ªG·|«ç¼Ë¡A¤£ª¾±zı±o§´·í§_¡H
¬°¤F·¾³qªº¶¶ºZ¡A°²³]¼Æ¦r¥²¶·¤@P¡A¥ý¥Î§Úªº¼Æ¦r¡A±z¦³³ßÅwªº¨ä¥¦°²³]¡A±z¦A×§ï¡Cº¥ý¡A¥uºâ¸ÕÅç²Õ¡A¦¬®×¤H¼Æ¡A2012¦~©³«e66¦ì¡A2013¦~1~6¤ë¦¬66¦ì¡A2013¦~7~12¤ë¦¬40¦ì¡A2014¦~1~7¤ë¦¬56¦ì¡A822¥¼¯à²£¥Í§@¥Îªº±wªÌ¦û10%(³o¼Ë¤l¤ñ¸û¦n³B²z«Üµu®É¶¡´N´c¤Æªº·¥ºÝÈ)¡A822§@¥Î¦¨NEDªº±wªÌ¦û10%(³o¼Ë¤l¤ñ¸û¦n³B²z¥i¥Hºû«ù«Ü¤[®É¶¡³£¤£´c¤Æªº·¥ºÝÈ)¡C
¥ý·Q¹³1¤ë©³¸ÕÅç²Õ¹F¨ì0.5ªºÁ`¦s¬¡¾÷²vªº´c¤Æ¤H¼Æ¥X²{¤F¡A´N´¦¶}¬Ýµª®×¡A±z¥u·|¬Ý¨ì¨âºØ¼Æ¾Ú¡A´c¤Æªº¼Æ¾Ú©MÁÙ¨S´c¤Æªº³]¸ê®Æ(¥¢Ápªº³]¸ê®Æ³oùØ¥ý¤£³B²z¡A¦]¬°¥un¤H¼Æ¤£¦h¡A¼vÅT´N¤£¤j)¡A´c¤Æªº±wªÌ´N«ö·Ó´c¤Æ®É¶¡ªøµu°µ±Æ§Ç¡A´c¤Æªº±wªÌ¥i¯à¨Ó¦Û©ó¤Wzªº®É¶¡°Ï¹jªº¥ô¤@°Ï¬q¡A¦ý·Ó±`²z¡A±q¤ñ¸û¦¦¬®×ªº°Ï¬qªº´c¤Æ¤H¼Æ·|¤ñ¸û¦h¡A¤ñ¸û±ß¦¬®×ªº°Ï¬q´c¤Æ¤H¼Æ·|¤ñ¸û¤Ö¡C´c¤Æ¤H¼Æ±Æ§Ç§¹«á¡A¹F¨ì´c¤Æ®É¶¡±Æ¦b³Ì¤[ªº¨º¤@Ó¡A¤]´N¬O±zªº¨Ò¤l¤¤ªº²Ä76¦ì(±Æ§Ç«á)¡A¤]¥i¥H»¡´N¬Oè¦n¹F¨ì0.5ªºÁ`¦s¬¡¾÷²vªº¨º¤@¦ì¡A§Ú̺ٳoӼƦr¬°m¡A¥Lªº´c¤Æ®É¶¡§ÚÌ¥ÎT¨Óªí¥Ü¡C²{¦b³]¸ê®Æn¤À¨â²Õ¡A²Ä¤@²Õ¬O¤Ö¼Æ¦¦¥¢Ápªº³]¸ê®Æ¤Î¤ñ¸û±ß¦¬®×ªº±wªÌ¡A·í´¦¶}µª®×®É¡A¥un´c¤Æ®É¶¡¤´¥¼½T©w¥B¦b´¦¶}¨º¤@¨è¥¼´c¤Æ®É¶¡¤p©óTªº¡A³£n±Æ¦b³o¤@²Õ¡A³o¤@²Õ¬O¥Î¨ÓpºâÁ`¦s¬¡¾÷²v±q1°¨ì0.5®É¦p¦ó¼vÅTmÓ¤w´c¤Æ±wªÌ¨ä¾÷²v¤U°ªº³t«×¡C¥t¥~¤@²Õ¬O´c¤Æ®É¶¡¤]¥¼½T©w¡A¦ý¬O¬O¦]¬°¦b¦´Á¦¬®×¥BÃĮĵo´§±o«Ü¦n¡A¤@ª½³£¨S¦³´c¤Æ¡A¥L̪º¥¼´c¤Æ®É¶¡¤j©óT¡A´N±Æ¦b²Ä¤G²Õ¡C¦´Á¦¬®×ªº±wªÌ¡A¦pªG¤£¬OÅܦ¨¤w´c¤Æ¼Æ¾Ú¡A´N¬O·|¦¨¬°²Ä¤G²Õªº³]¸ê®Æ¡F±ß´Áªº¦¬®×±wªÌ¡A¦pªG¤£¬OÅܦ¨¤w´c¤Æ¼Æ¾Ú¡A´N·|¦¨¬°²Ä¤@²Õªº³]¸ê®Æ¡A¥¢Ápªº±wªÌ´X¥G¤j³¡¥÷³£¦b²Ä¤@²Õªº³]¸ê®Æ¡C²Ä¤@²Õªº³]¸ê®Æ»PmÓ¤w´c¤Æªº¼Æ¾Ú¦@¦P¨Ó¨M©w0.5ªºÁ`¦s¬¡¾÷²v¦ó®É¥X²{¡A¤]´N¬O»¡¤¤¦ì¼ÆPFS¦ó®É¥X²{¡A²Ä¤G²Õªº³]¸ê®Æ¡A¤£ºÞ¥L̳]¦h¤[¡A¹ï¤¤¦ì¼ÆFPS¨S¦³¼vÅT¡C
§ÚÁ|¨âÓ¨Ò¤l¡A±z¨Óºâºâ¬Ý¡C¥ý¥Î±zªºÁ|¨Ò¡A1¤ë©³¹F176¤H´c¤Æ¡A¨ä¤¤¹ï·Ó²Õ100¤H¡A¸ÕÅç²Õ76¤H¡A§Ų́Ӻâºâ¬Ý76¬O§_´N¬O¹F¨ì0.5ªºÁ`¦s¬¡¾÷²vªºm¨ºÓ¼Æ¦r¡A¥H¤Î¦pªG¹F¨ì¤F¡A¤¤¦ì¼ÆPFS¬O¦h¤Ö¡C
²Ä¤@Ó¨Ò¤lªº°²³]¥Î³Ì«O¦uªº¤è¦¡¡A¤w´c¤ÆªºmÓ±wªÌ¥þ³¡¨Ó¦Û©ó2012¦~¦~©³«eªº66¦ì»P2013¦~1~6¤ëªº66¦ì¡AÁ`¦@³o132¦ì±wªÌ¤¤¡A¦]¦¹2014¦~1~7¤ëªº56¦ì»P2013¦~7~12¤ëªº40¦ì±wªÌ¡A°£¤F10% ªº¤ñ¨Ò¦¨¬°¤w´c¤Æ¼Æ¾Ú¥~¡A¨ä¥¦ªº86¤H³£¬O¥¼´c¤Æ®É¶¡¤p©óTªº³]¸ê®Æ¡C²{¦b¥Î³o86¦ì¤p©óTªº³]¸ê®Æ»PmÓ¤w´c¤Æ¸ê®Æ¨Ó°µºtºâ¡A¬Ý¬Ý¬O§_76¬O¤£¬O¯uªº¬Om¡Hm¥i¯à¤j©ó76¤]¥i¯à¤p©ó76¡An¥Î¤ñ¸û±µªñ¯u¹ê±¡ªpªº¤è¦¡¨Ó°µ¸Õºâ¡C¨Ì±zªº¸Õºâªí¡A±z¬O¥ý¦³28¦ì¤w´c¤Æ¼Æ¾Ú¡A±µ¤U¨Ó88¦ì³]¡A¦A±µ¤U¨Ó48¦ì¤w´c¤Æ¼Æ¾Ú¡A¦¹®É¦b¤w´c¤Æ¹F76¤H®É¹F¨ì0.5ªºÁ`¦s¬¡¾÷²v¡C²{¦b§Ú̥Υi¯à§ó¶Kªñ¨Æ¹êªº¤èªk¡A¥ý¦³228¤Hªº10%¤]´N¬O23¤H¤w´c¤Æ¡AµM«á±µ¤U¨Ó¤À°t³]¸ê®Æ86¤H»P76-23=53¤H¤w´c¤Æ¼Æ¾Ú¡A¥æ¤eµÛ¼vÅTKM¨ç¼Æ¤U°ªº¾÷²v©M¹Ï«¬¡AÁ|Ó¨Ò¡A«ö®É¶¡±Æ§Ç¡A¨C5Ó³]¸ê®Æ´Nºò±µµÛ°t3Ó¤w´c¤Æ¼Æ¾Ú¡A¦p¦¹5Ó°t¤TÓ¡AÅýKM¨ç¼Æ¤£Â_¤U°¡Aª½¨ì0.5ªºÁ`¦s¬¡¾÷²v¥X²{¬°¤î¡A¬Ý¬Ý³]¸ê®Æ¹F¨ì´X¦ì¥H¤Îm¬O¦h¤Ö®É¡A0.5ªºÁ`¦s¬¡¾÷²v¥X²{¡C°²³]¯uªº¬O86¦ì³]¸ê®Æ»P76Ó¤w´c¤Æ¼Æ¾Ú¥i¥H¹F¨ì0.5ªºÁ`¦s¬¡¾÷²v¡A¦]¬°²Ä86¦ì³]¸ê®Æªº¥¼´c¤Æ®É¶¡¬O±q2013¦~7¤ë¨ì2015¦~1¤ë¡A¦@¬O19Ó¤ë¡A¤S¦]¬°T(²ÄmÓ¤w´c¤Æ±wªÌ¡A¥Lªº´c¤Æ®É¶¡´N¬O¤¤¦ì¼ÆPFS)¤@©w¤j©ó«e±ªº86¦ìªº³]¸ê®Æªº¥ô¦ó¤@Ó¡A¦]¦¹T¤j©ó19¡C
¥t¤@Ó¨Ò¤l¬O·¥ºÝªº¨Ò¤l¡A´N¬O¤w´c¤Æªº¼Æ¾Ú³£¬O±q¦¦¬®×ªº±wªÌ¨Óªº¡A°£¤F10%ªº822¥¼¯àµo´§ÃĮġA¥H¤Î10%ªº±wªÌÄÝ©óNEDªºª¬ªp·|«Ü¤[¤~´c¤Æªº¨Ò¥~¡C¥ý°²³]³o¤@Ó¨Ò¤lªºm¤]¬O76¦ì¡A¦ý¦]¬°³o¤@¨Òªº²Ä¤@²Õ(«e±¦³©w¸q¹L²Ä¤@²Õ©M²Ä¤G²Õ)³]¸ê®Æ·|¤ñ¤W¤@¨Ò¦h«Ü¦h¡A©Ò¥H³o¤@¨Òªºm¤@©w¤p©ó76¡A¹ê»Úªºm½Ð±z¸Õºâ¬Ý¬Ý¡C¤@¼Ë¥Î¸Õºâªí¨ÓºâKM¨ç¼Æ«ç»ò±q1¤U°¨ì0.5¡AÁÙ¬O¥ý¦³23¤H«Ü§Ö´N´c¤Æ¤F¡A76-23=53¡A³Ì¦h53¤H¥þ³¡¨Ó¦Û©ó2012¦~¦~©³«e¦¬®×ªº±wªÌ¡A2012¦~¦~©³«e¦¬66¤H¡A¦³10%¬ù7¤H¬ONEDªº±wªÌ¡A³o7¦ìNEDªº±wªÌ·|«Ü¤[¤~´c¤Æ¡A¦]¦¹³Ì¦h53¤Hªº¤w´c¤Æ¼Æ¾Ú¥þ³¡¨Ó¦Û©ó66-7=59³o59¦ì±wªÌ¡A¤]´N¬O»¡¡A¦b2012¦~¦~©³¥H«á¦¬®×ªº66+40+56¤H=162¤H¡A°£¤F10%ÃĮĤ£¦nªº¤§¥~¡A¦b¦¹¨Ò¤¤¡A¥þ³¡¬O¥¼´c¤Æªº³]¸ê®Æ¡A2013¦~1¤ë¦¬®×ªº´N¬O25+Ó¤ë¡A2013¦~5¤ë¦¬®×ªº´N¬O20+Ó¤ë¡A¨Ì¦¹Ãþ±À
ÁÂÁ±z´£¨Ñªº¸ê®Æ
¦ý¨Ì¾Ú©w¸q¡G
¡K³o類¥Hµo¥Í¡u¸~½F惡¤Æ¡v¬°Æ[¹î¨Æ¥óªºµû¦ô«ü¼Ð±`¥Îªº¦³Progression-free survival (PFS)©MTime to progression (TTP)¡A³o兩Óµû¦ô«ü¼Ð©w¸qµy¦³不¦P¡APFS©w¸qªº¨Æ¥ó¥]¬A¡u¸~½F惡¤Æ¡v©M¡u¦º¤`¡v¡A¥HPFS¬°µû¦ô«ü¼Ðªº臨§É¸ÕÅç¡AÆ[¹î¨ü¸ÕªÌ±q¶i¤J¸ÕÅç¨ì¸~½Fµo¥Í惡¤Æ©Î¦º¤`ªº®É¶¡ªø度¡A¨ü¸ÕªÌ¥un¡u¸~½F惡¤Æ¡v©Î¡u¦º¤`¡v¤GªÌ¨ä¤@¥ýµo¥Í¡A«h¹F¨ì¬ã¨sªº²×ÂI¡A¦¹¤@Æ[¹î®É¶¡ªø度§Y¬O¸ÕÅç©Òn¦¬¶°¤ÀªRªº數¾Ú¡F¦ÓTTP©w¸qªº¨Æ¥ó¶È¦³¡u¸~½F惡¤Æ¡v¡A不¥]¬A¡u¦º¤`¡v¡K
¦º¤`ªÌ¡A¦pªG¥L¬O¥ý´c¤Æ¦A¦º¤`¡A¨º»ò¥LªºPFS©MOS³£¤w¸g¦b¤£¦Pªº®É¶¡½T©w¤F¡A¹ï³oÓÁ{§É¹êÅç°^Ämªº²Îp¼Æ¾Ú¤£·|¦AÅܰʤF¡F¦pªG¥LÁÙ¨SÆ[¹î¨ì´c¤Æ´N¦º¤`¡A¨º»ò¥LªºPFS©MOS¬O¦P¤@Ӯɶ¡¡A¤]½T©w¤F¡A¹ï³oÓÁ{§É¹êÅç°^Ämªº²Îp¼Æ¾Ú¤]¤£·|¦AÅܰʤF¡C¦]¦¹¤p§Ìı±o¡y¦º¤`ªÌ¬O°h¥XÁ{§Éªº¡z³o¥y¸Ü§ï¦¨¡y¦º¤`ªÌ¤£¦A¹ïÁ{§É¹êÅ窺²Îp¼Æ¦r²£¥ÍÅܰʡz¤ñ¸û§´·í¡C
½Í¨ìÃÒ©Òµ|¡Aµoı¤j®a¦³Ó¿ù»~ªº·§©À¡A´N¬O"IPO¤£¨ì10±iªº¤H¤£¥Î½Ò"¡C
¨ä¹ê¡A¾Ú§Ú¤F¸Ñ¡A³o¬O¿ù»~ªº¡A¦Ó¬O"ÄݩӾP¨ú±o¦U¸Óªì¦¸¤W¥«¡B¤WÂd¤½¥qªÑ²¼¼Æ¶q¦b 10,000 ªÑ¥H¤U"ªº¤~¤£½Ò¡C(½Ð°Ñ¦Ò¤U¤èªº°êµ|§½ºô¯¸)
http://www.mof.gov.tw/public/Attachment/3871541926.pdf
´«¥y¸Ü»¡¡AÀ³¸Ó¥u¦³¤½¥qû¤u»{ÁÊ¥H¤Î¸ß°éªº¤H¤~¦³³o¸ê®æ¤~¬O¡A¦]¬°°£¦¹¥H¥~¡A¸Ó¤£ÄÝ©ó"ÄݩӾP¨ú±o"¡C
Y¦³¿ù»~¡A©|½Ð¤£§[«ü¥¿^^
¬Ý¨Ó¯uªº¸Ó¦Ò¼{³¬¼L¤F ÁÂÁ¤j®a!
±q¤U±¤G«h·s»D³ø¾É, palbociclibÁÙ¨S®³¨ìFDA·sÃĤW¥«³\¥i, ¥u¬OÀò±oÀu¥ý¼f¬d¸ê®æ, ¼f¬dºI¤î¤é´Á¬°2015-4-13.
¦b2015-4-13¤§«e, FDA·|¤½§i¬O§_³q¹L¼f¬d.
According to studies, inhibition of these proteins will slow down the growth of cancer.
½÷·çªºPalbociclib¥u¬O§í¨î©M°§CÀù²ÓMªº¥Í´Þ¤O, ©Ò¥H¯à©µªøÀù²ÓM´c¤Æªº®É¶¡. ¥¦¤£¯à®ø·ÀÀù(·F)²ÓM.
µ¥¨ìÀù²ÓM²£¥Í§ÜÃÄ©Ê, ¨ä¥Í´Þ¤O©MÂX´²¤O§ó±j, ©Ò¥HÁ`¦s¬¡´Á(OS)¼W¥[¤£¦h.
2014-10-16 CDK4/6¥«³õ¶}±Ò¦b±æ¡XFDAÀu¥ý¼f¬d½÷·ç¨Å¸¢Àù©ú¬PÃÄpalbociclib
½÷·ç(Pfizer)ªñ¤é«Å¥¬¡AFDA¤w±µ¨ü¼f¬dpalbociclib·sÃÄ¥Ó½Ð(NDA)¡A¦P®É¤w±Â¤©Àu¥ý¼f¬d¸ê®æ(Priority Review Status)¡A
¦}¤w«ü©w³B¤èÃĥΤ᦬¶Oªk(PDUFA)¥Ø¼Ð¤é´Á¬°2015¦~4¤ë13¤é¡CÀu¥ý¼f¬d¸ê®æ·N¨ýµÛFDA±N¦b6Ӥ뤺§¹¦¨palbociclib NDAªº¼f¬d¡A¬Û¤ñ±`³Wªº10Ó¤ë¼f¬d©P´ÁÁYµu¤F4Ó¤ë¡C
¦pªGÀò§å¡Apalbociclib+µÜ¦±Ðü(letrozole)Áp¦XÀøªk§@¬°ER+/HER2-±ß´Á¨Å¸¢Àùªº¤@½uÀøªk¡A±N¬°¦¨¤d¤W¸UÂಾ©Ê¨Å¸¢Àù±wªÌ´£¨Ñ¤@Ó«nªº·s¿ï¾Ü¡C
2015-1-11 Pfizer Inc. (NYSE:PFE) Expects Early Approval of Drug for Breast Cancer
Pfizer Inc. (NYSE:PFE) is working on a new drug for treatment of breast cancer. The drug is called palbociclib.
Pfizer Inc. (NYSE:PFE) is currently having talks with the FDA of US to get them to approve the drug early.
The FDA accepted the application of palbociclib in October 2014. The breast cancer drug was granted a high status ¡V Priority Review.
As a result, the time taken for reviewing the drug decreased to six months from 10.
Pfizer Inc. (NYSE:PFE) says that this decision by the FDA does not require a meeting of the advisory committee.
Spokesperson from FDA, Tara Goodin, said that palbociclib will be completely and thoroughly reviewed by the FDA, whether or not Oncologic Drugs Advisory Committee evaluates it.
Jefferies¡¦ analyst, Jeffrey Holford, said that Pfizer Inc. (NYSE:PFE) gave a statement that since the Advisory Committee is not meeting to approve the breast cancer drug,
therefore, Pfizer Inc. (NYSE:PFE) are confident that palbociclib will be approved by April. ½÷·ç¦Û«Hpalbociclib±N¦b2015¦~4¤ëÀò±o¼f§å.
FDA earlier gave an approval date of April 13. The statement by Pfizer Inc. (NYSE:PFE) suggests that the company would receive the approval that they seek by this date.
As a result of this announcement, the stocks of Pfizer Inc. (NYSE:PFE) increased by 2.04%. Palbociclib will be sold as Ibrace expectantly.
Letrozole is another drug for treatment of breast cancer, which has been approved by the FDA.
Ibrace and letrozole will be used as a combination together to treat breast cancer in women who have crossed their age for menopause.
The advanced breast cancer patients will be those who have not received earlier treatments. The proteins CDK 4 and 6 help in the growth and spreading of tumor cells.
Palbociclib targets these proteins. According to studies, inhibition of these proteins will slow down the growth of cancer.
In 2013, the FDA gave the drug a designation of Breakthrough Therapy. For many past years, the pharmaceutical companies have used
this approach of inhibiting the CDK proteins to treat cancer. But so far no such efforts by other companies have been successful.
The reason was that severe side-effects were noticed in patients that were being treated with drugs targeting all the CDK classes.
Pfizer Inc. (NYSE:PFE) was successful because it only targeted the CDK 4 and 6 proteins; not all of the classes. According to studies to investigate the drug,
palbociclib slowed down the cancer growth for over 20 months. The treatments that are available in the market are those that stall cancer spread for 10 months only.
Still, it is not known for how long the patients¡¦ survival is extended. Analysts estimate that palbociclib can potentially generate annual sales worth $3 billion.
Mr. Holford estimates that the annual sales will increase by $5 billion due to the drug. JPMorgan estimate that by 2020, the drug will bring home $4 billion.
Pfizer Inc. (NYSE:PFE) say that they are planning to bring the drug in the
Palbociclib ÁÙ¨S¦³®³¨ìFDA ÃÄÃÒ
¦³¦nªºPFS ¨S¦³¦nªºOS ±N¥¢¥h·sÃĬãµoªº²×·¥¥Øªº»P»ùÈ
·PÁ±zªá¶O¤j¶qªº¤ß¤O®É¶¡¬°¤p§Ì¸Ô²Ó¦a¸Ñ»¡
¹ï©ópºâ ¤¤¦ìPFS ªºÃöÁä°ÝÃD --- ±ß¶i¸ÕÅ窺±wªÌ ¦b¸Ñª¼®É ¤´¥¼´c¤Æ ³o¨Ç¸ê®Æ«ç»ò³B²z
°O±o´¿´N±Ð©ó±z Áö±o±z¶}ÄÀ ¤p§Ì«o»~¸Ñ¦Ü¤µ
¤£µM¤]¤£·|¦b³oÓÄø°ÝÃD¤W¥´Âà
¤µÁö±o¥HÂç²M ´N¬O¥²¶·¥H³]¸ê®Æ¨Ó³B²zpºâ
³o¤]Åã¥Ü ·í¸Ñª¼®É ¤£ºÞ¦³µL³Q¢(2015.9 ©Î¤§«e) ³]¸ê®Æ¤H¼Æ´X¥G·|¶W¹L88¤H
«ö·Ó¸Õºâ ·í³]¥[´c¤Æ¤H¼Æ ¶W¹L(88+76) ¥Î©Ô»ôªk¥H¤é¾ä¤Ñ¦ôºâªº¤è¦¡¶Õ±N¶W¦ô °£«D¸ÕÅç²Õªº´c¤Æ¤H¼Æ¹é¹éµL´X(µL³Q¢¸Ñª¼ªº±¡ªp)
³o¯uªº¤£¦nª± §Ë¿ùÆ[©À §C¦ôÅܶW¦ô ÁÙ¯u¥O¤HµLªk½Õ¾A!
©Î³\´N´Á«Ý¬Ý¬Ý 822ªº¤¤¦ìOS¥i¦³¶W¤Zªºªí²{?
³o¤]Åý¤H·Q°_ ¥Ñ½÷·ç¤½¥q¬ãµo¥B´£¦Àò±oÃÄÃÒªº palbociclib
¥¦ªº¾AÀ³¯g¬OER(+) HER2(¡Ð)ªºMBC±wªÌ ¤p§Ì»{¬° Palbociclib ¬O822ªº¹ï¤âÃÄ
palbociclib ¬OCDK 4/6§í»s¾¯¡A¦®¦bªý¤î²ÓM¶g´Á¶iµ{ §í¨î²ÓM¼W´Þ©M²ÓMDNAªº¦X¦¨
Palbociclib ¯à¥H¤G´Áªº¼Æ¾Ú ¦b¤£¨ì60¤Ñªº®É¶¡«KÀòÃÄÃÒ(2014.8.18 ~ 2014.10.13)
¬O palbociclib ÃĮİ÷¦n ÁÙ¬O½÷·ç°÷¤O?
¾Ú³ø¾É http://www.ascopost.com/issues/may-1,-2014/paloma-1-trial-finds-palbociclibletrozole-doubles-progression-free-survival-in-metastatic-breast-cancer.aspx
³oÓ¦W¬°PALOMA-1 ªº¤G´Á¸ÕÅç ¤À¨âÓ³¡¥÷
1. ER(+) HER2(¡Ð)¥B°±¸gªºMBC±wªÌ ¥¦ªº¤¤¦ìPFS ( palbociclib + letrozole ) :( letrozole ) ¬°26.1Ó¤ë : 5.7Ó¤ë ¡]P <0.0001¡^
2. ER(+) HER2(¡Ð)¥B¨ã¦³(CCND1 amplification and/or loss of p16) ªºMBC±wªÌ ¤¤¦ìPFS ( palbociclib + letrozole ) :( letrozole ) ¬°18.1Ó¤ë : 11Ó¤ë ¡]P <0.0046¡^
¨â³¡¥÷ªº¤¤¦ìPFS Á`p ( palbociclib + letrozole ) :( letrozole ) ¬° 20.2Ó¤ë : 10.2Ó¤ë ¡] P = .0004¡^
¤¤¦ìOS ( palbociclib + letrozole ) :( letrozole ) ¬° 37.5Ó¤ë : 33.3Ó¤ë (µL²Îp¾ÇÅãµÛ®t²§)
Á{§ÉÀò¯q²v ( §¹¥þ©M³¡¤À¤ÏÀ³¥[¤W¯e¯féw ) ¤À§O¬° 81 ¢H ©M 58 ¢H
¸ÕÅçµ²§ô®É ¤´¦bªvÀøªº±wªÌ ( palbociclib + letrozole ) 23 ¢H VS ³æ¿Wletrozole 10 ¢H ³Ì±`¨£ªº°±¤îªvÀøì¦]¬O¯e¯f¶i®i
³o¼Ëªº¼Æ¾Ú«Ü´Î¶Ü?
ÁöµM ¤¤¦ìPFS ¦³ÅãµÛ¦¨ªø ¦ý¬OÁ`¥Í¦s«ü¼ÐOS «oµLÅãµÛ§ïµ½ ±wªÌ¨Ã¥¼±q·sÃÄÀò±o¥Í¦s§Q¯q
¸ÕÅç²Õªº¥ÎÃÄÀW²v¬° 125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
¦b¸ÕÅçµ²§ô®É ¸ÕÅç²Õ¤´¦bªvÀøªº±wªÌ ¦³ 23 ¢H ©ÎÅã¥Ü¥Xªñ77 %ªº±wªÌ¦³§ÜÃĩʪº°ÝÃD ¾ÉPÃĪ«¥¢®Ä ²£¥Í¯e¯f¶i®i
±q³oÓ¨Ò¤l ER(+) HER2(-)ªºMBC±wªÌ ©Î³\¸~½F´c©Ê¨S¦³¨º»ò°ª
¦]¬°HER2(¡Ð) ´_µo´c©Ê°§C µL»Ý¨Ï¥ÎHerceptin ¤S¦]¬°ER(+) ©Ò¥H³æ¿W¨Ï¥Îletrozole ´N¥i§â¤¤¦ìOS©Ôªø¨ì33.3 Ó¤ë
¨º¤£¸Tn°Ý palbociclib ªº¨¤¦â¦bþ¸Ì?
³o¼Ë¤]¯à¥Î¤G´Á¼Æ¾Ú¨Ó´£¦Àò±oÃÄÃÒ ±M·~©M«D±M·~¤§¶¡ªº¬Ýªk³º¦p¦¹~²§ Åý¤H¦³¹j¦æ¦p¹j¤s¤§¹Ä
©Î³\ 822 ªºÁ{§É¤T´Á¥i±Ä¶}©ñ¦¡¸ÕÅç ±N¨ä¤¤¤@²Õ¦bÀøµ{µ²§ô«á Ä~Äò©T©w¶g´Á¦a¬IÃÄ ª½¨ì¯e¯f¶i®i¬°¤î ¨ÓÆ[¹î822ªºÃĮķ¥
Ãö©ó¨ÅÀùªº¶Pº¸»XÀøªk ³o½g¤¶²ÐÁÙº¡¸Ô²Óªº https://www1.cgmh.org.tw/intr/intr5/c6210/breast%20cancer%20hormone%20therapy.html
¥H¤W»¡ªk ¶È¨Ñ°Ñ¦Ò ÁÂÁ¤j®a!
°Ú«¢! ¹ï¤£°_ ¦Ñ¬O»~¾É¤j®a ¬Ý¨ÓÀ³¸Ó³¬¤W¼L¤Ú¤F
©¯¦n¦³¤p©_¤jªº«ü¾É ¤£µM»~¤H»~¤v ¤´¤£¦Ûª¾ ¬O¬°¸o¹L
«D±`ÁÂÁ¤p©_¤jªº«ü¾É ·P®¦!
¤p§ÌºÉ¤O¥h¸ÑÄÀ¬Ý¬Ý¡AY¦³Ã㤣¹F·N¤§³B¡A¦AÄ~Äò°Q½×¡C
¡y¸ÕÅç²Õ228¤Hªº³]¸ê®Æ·|¤j©ó88¤H¶Ü?¡z
§Ú·Q±z¥i¯à§â³]¸ê®Æ©w¸q¬°¥¢Ápªº±wªÌ¤F¡A¥¢Ápªº±wªÌ¥u¬O³]¸ê®Æªº¤@¤p³¡¤À¡A´¦¶}¬Ýµª®×®É¡A©|¥¼´c¤Æªº±wªÌ¤~¬O³]¸ê®Æªº³Ì¤j³¡¤À¡A°²³]¯E¹©²{¦b´¦¶}¬Ýµª®×¡AS¤p©j¥h¦~3¤ë¦¬®×¡A¨ì²{¦b¬ù¤QÓ¤ë¡A¤´¨S¦³´c¤Æ¡A²Îp¼Æ¦r¬ö¿ý¬°10+Ó¤ë¡A¦o¥i¯à¦A¹L¤@Ó¤ë´N´c¤Æ¡A¤]¥i¯à36Ó¤ë«á´c¤Æ¡A¦]¬°n°µ²Îp¤ÀªR¤F¡AS¤p©j´N¬Oµn°O¬°10+Ó¤ë¡C¦pªG¦³¤@Ó¥h¦~2¤ë¦¬®×ªº±wªÌ¡A¦o¨ì¥h¦~12¤ë«á±q¦¹¥¢Áp¡A¨º»ò¦o¤]¬Oµn°O¬°10+Ó¤ë¡A¦ý³o¦ì10+Ӥ몺±wªÌ»PS¤p©jªº10+Ӥ뤣¤Ó¤@¼Ë¡A¦pªG¯E¹©±ß¤@ÂI¸Ñª¼¡AS¤p©jªº¼Æ¦rÁÙ·|ÅܤơA¦ý³o¦ì¥h¦~2¤ë¦¬®×ªº±wªÌ¡A¦o¬OÄÝ©ó¥¢Áp¤H¤f¡APFS¤ÀªR©MOS¤ÀªR³£¬O¬ö¿ý¬°10+Ó¤ë¡A¤£·|¦A¦³¥ô¦óÅܤƤF¡C³q±`³o¼Ë¤l¦]¥¢Ápªº³]¸ê®Æ¦ûÁ`¸ÕÅç¤H¼Æªº¤ñ¨Ò¤£·|¤Ó°ª¡A¤j¬ù¤Q´XӦʤÀ¤ñ¡A¦b¦¹342¤HªºÁ{§É¸ÕÅ礤¡A¯E¹©§ìªº¬O342-284=58¤H¡A¥un¥¢Áp¤H¤f¤£¶W¹L58¤H¡A³£¦b¸ÕÅ窺³]p°²³]½d³ò¤º¡C(¯E¹©¬O§_§ì58¤H¬°¸ÕÅç³]p¥i¯àªº¥¢Áp¤H¼Æ¡A¤p§Ì¤£¯à§¹¥þ½T©w¡A¬O¥Î±À´úªº¡A³oÂI°Ñ¦Ò´N¦n¡C)
¥Ñ¤Wzªº¸ÑÄÀ¡A¥ô¦ó®ÉÔ´¦¶}µª®×¡A´N¥u¦³¤w´c¤Æ±wªÌªº´c¤Æ®É¶¡¸ê®Æ¡A¥H¤Î´c¤Æ®É¶¡¤´¥¼ª¾ªº³]¸ê®Æ¨âºØ¸ê®Æ¡A¥u¦³³o¨âºØ¼Æ¾Ú¡A¤w´c¤Æ±wªÌªº´c¤Æ®É¶¡¸ê®Æ¤w¸g¬O§¹¥þ½T©wªº¼Æ¾Ú¡A¤£ºÞ¦Aµ¥¦h¤[¡A¼Æ¦r³£¤£·|¦A§ïÅܤF¡C´c¤Æ®É¶¡¤´¥¼ª¾ªº³]¸ê®Æ¥i¥H¤À¦¨¤TÃþ¼Æ¾Ú¡A¤@Ãþ¬O¥¢Ápªº³]¸ê®Æ¡A³oÓ¤]¤£·|¦AÀHµÛ®É¶¡ªº±À¶i¦Ó§ïÅܤF¡F¤@Ãþ¬O¦]¬°¤ñ¸û±ß¤~¶i¤J¦¬®×ªº¸ÕÅç²Õ±wªÌ¡A¦]¬°¶i¤J¸ÕÅç®É¶¡¤Óµu¡A¤j³¡¤À³£ÁÙ¨S´c¤Æ¡A¥h¦~1~7¤ë¦¬®×ªº¸ÕÅç²Õ±wªÌ³£¬OÄÝ©ó³o¤@Ãþ¡AY¦AÆ[¹î¤[¤@ÂIªº®É¶¡¡A¤~¯àª¾¹DÃĪ«¦b¥L̨¤WªºÃĮĦp¦ó¡F¥t¤@Ãþ¬OÃĪ«¦b¥L̨¤W§@¥Î±o¬Û·í¦nªº¦´Á¦¬®×±wªÌ¡A¨Ò¦p¦b2012¦~¦~©³«e¦¬®×ªº¸ÕÅç²Õ±wªÌ¡A¥LÌ¥þ³¡¸g¾ú¶W¹L24Ó¤ë¥H¤Wªº®É¶¡¡A¦]¬°ÁÙ¨S´c¤Æ¡A²{¦b´¦¶}¬Ýµª®×¡AÁÙ¬O¨S´c¤Æ¡A¦]¦¹¤]¬Oµn°O¬°³]¸ê®Æ¡C
¦b±zªº¨Ò¤l¤¤¡A¡y°²Y¸Ñª¼®ÉÁ`´c¤Æ¤H¼Æ¬O176 ¥B°²³]¹ï·Ó²Õ¦³100¤H´c¤Æ ¨º´N¬O¸ÕÅç²Õ¦³76 ¤H´c¤Æ¡z¡A¬JµM¸ÕÅç²Õ¦³76¤H´c¤Æ¡A¨º»ò¸ÕÅç²Õªº³]¸ê®Æ´N¬O228-76=152¤H¡A³o152¤H¦³¥¢Ápªº¡B¦³¸û±ß´Á¤~¶i¤J¸ÕÅ窺¡B¦³ÃĮĵo´§±o«Ü¦nªº¦´Á¦¬®×±wªÌ¡A¥L̪º´c¤Æ®É¶¡´N¬O¦b¸Ñª¼®É¨S¦³¿ìªk§¹¥þ½T©w¡A¦]¦¹ºÙ¬°³]¸ê®Æ¡A´N¦]¬°¦s¬¡¤ÀªR·|¦³«Ü¦hªº³]¸ê®Æ¡A©Ò¥H¤~¥ÎKM¨ç¼Æ¨Ó¸Ñ¨M¡C
¡y¥Î³oÓ·í°ò¦ ¨Ó¸Õºâ·í³]¸ê®Æ¬O¦h¤Ö®É 822ªºÁ`¦s¬¡¾÷²vèè¦n·|¬ï¶V0.5
¸Õ¤F´X¦¸ ·í³]¸ê®Æ¤H¼Æ¹F88 ¤H (¸ÕÅç²Õ¦³76 ¤H´c¤Æ) Á`¦s¬¡¾÷²vèè¦n·|¬ï¶V0.5 (¸Õºâªí¦C©ó³Ì©³ºÝ ½Ð°Ñ¦Ò)
³o¬O§_ªí¥Ü ·í³]¸ê®Æ¤H¼Æ¬°88¤H®É 822ªº¤¤¦ìPFS©Î»P¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼Æ¬ù²¤¬Û·í( §â©Ò¦³±wªÌ¬Ý¦¨¦P®É¶i¤J¸ÕÅ窺·í¤é°_ºâ)
·í¸Ñª¼®É ³]¸ê®Æ¤H¼Æ¤Ö©ó88¤H®É ¤¤¦ìPFS·|¤ñ¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼ÆÁÙªø??? ¤Ï¤§ «hn¥´§é??? ³o¼Ëªº»¡ªk¹ï¶Ü???¡z
§Ú¸ÕµÛ«ö·Ó±zªº¨Ò¤l¨Ó±À¡A±z¬Ý¬Ý¸ò±zªº·Qªk¤@¼Ë§_¡H
±zªº¸Õºâªíªººâªk¡A¦b¥[Åv¥§¡¤èªk¤¤¡AÀ³¸Ó¸ÑŪ¬°¡A°²³]¦³76¤H´c¤Æ¤F¡A³o76¤H¥ý
«ö·Ó´c¤Æ®É¶¡°µ±Æ§Ç¡A§Ṵ́²³]´N¦b³oӤ멳¹F¨ì76¤H´c¤Æ¡A©Ò¥H³o²Ä76¤Hªº´c¤Æ®É¶¡¬ö¿ý¬°20Ó¤ë(±zªº¥[Åv¥§¡¦b2013¦~5¤ë¡A¹ï¶Ü¡H)¡A¦]¦¹´N°²³]¥þ³¡ªº228¦ì¸ÕÅç²Õ±wªÌ³£¦b2013¦~5¤ë¦¬®×¡A¦]¬°¤ñ³o²Ä76Ó¤H´c¤Æ®É¶¡¡A¤]´N¬O20Ó¤ë¡AÁÙµuªº³]¸ê®Æ¦b¦¹¨Ò¤¤¬°88¤H¡A§ÚÌ¥²¶·°²³]³o88¤H¥þ³¡¬O¥¢Áp¡A©ÎªÌ¦b²Ä¤@Ӥ륢Áp¡B©ÎªÌ¦b²ÄÓ¤G¤ë¥¢Áp¡B©ÎªÌ¦b²Ä19Ӥ륢Áp¡A¨ä¾lªº228-88-76=64¤H³£ÁÙ¨S´c¤Æ¡A¥L̤]¬O³]¸ê®Æ¡A¬OÃĮĵo´§±o«Ü¦nªº±wªÌ¡A¦]¦¹¦b±zªº¥[Åv¥§¡¤èªk¤¤¡AY¦b³oӤ멳¹F¨ì76¤H¥B°µ¤F¸Ñª¼¡A¤¤¦ì¼ÆPFS´N¬O20Ó¤ë¡A¦]¬°¤w¸g¹F¨ìÁ`¦s¬¡¾÷²vèè¦n¬ï¶V0.5¤F¡C
¦A¨Ó¬Ý¹ê»Úªº¡A¦ý¤]¬O³ÌÃø¦ôºâªº¤¤¦ì¼ÆPFS¡C¤@¼Ë¨Ì·Ó±zªº¨Ò¤l¡A²Ä76¤H´c¤Æ®É¡A¦³88Ó³]¸ê®Æ¦b¸g¹L±Æ§Ç«áªº²Ä76¤Hªº´c¤Æ®É¶¡¤§«e¡A¦P®É¤]ªí¥Ü¦³64¦ì³]¸ê®Æ¬OÄÝ©óÃĮĵo´§±o«Ü¦n¡A¥L̸g¾ú¤F¶W¹L¸g±Æ§Ç«áªº³o²Ä76¤Hªº´c¤Æ®É¶¡«á¡A¤´³B©ó¥¼´c¤Æªºª¬ºA¡Cn«ç»ò¥h±Æ«e±ªº88Ó³]¸ê®Æ»P¤w¸g´c¤Æªº76¤Hªº¶¶§Ç¡H³oӱƪk¡A¦A«ç»ò±Æ¡A¨ä¹ê³£¥u¬O²q¡A¸ò¸Ñª¼ªº¼Æ¾Ú¥²¦³¤£¤pªº®t¶Z¡A§ÚÌ¥u¯à±q³Ì¦³¥i¯à©Êªº±Àªk¥h²q¡C¥ý¥Î§Ú¥Îªº¼Æ¦r¡A2013¦~6¤ë©³«e¸ÕÅç²Õ¦¬®×132¤H¡A2013¦~¤U¥b¦~¸ÕÅç²Õ¦¬®×¤H¼Æ40¤H¡A2014¦~¸ÕÅç²Õ¦¬®×¤H¼Æ56¤H¡A¥H¤Î¦³10%ªº¸ÕÅç²Õ¬OÄÝ©ó822´X¥G¨S¦³µo´§ÃĮĪº±wªÌ¡C2013¦~¤U¥b¦~¸ÕÅç²Õ¦¬®×¤H¼Æ40¤H+2014¦~¸ÕÅç²Õ¦¬®×¤H¼Æ56¤H=96¤H¡A¬OÄÝ©ó¸û±ß¦¬®×ªº±wªÌ¡A¦©±¼10%ªº´X¥G¨S¦³µo´§ÃĮĪº¤w´c¤Æ±wªÌ¡A¤´¦³¬ù86¦ì±wªÌ¡A³o86¦ì±wªÌ©|¥¼´c¤Æ¡A¦ý¸g¾ú¸ÕÅç®É¶¡¤S¤ñ¸ûµu¡A¦]¦¹³Ì¥i¯à³£¬OÄÝ©ó¤Wzªº88Ó³]¸ê®Æ¡A¨º¨Ì·Ó¤w´c¤Æ®É¶¡°µ±Æ§Çªº³o²Ä76¦ì¤w´c¤Æ±wªÌ¡A¦]¬°¥Lªº´c¤Æ®É¶¡¥²¶·¬O¤j©ó«e±ªº²Ä88Ó(«e±88¦ì±Æ§Ç«á³Ì¤j¨º¤@Ó¡A³Ì¦³¥i¯à¬O¦b2013¦~7¤ë¦¬®×ªº)¡A¦]¦¹³o¸g±Æ§Ç«áªº²Ä76¦ì´c¤Æ±wªÌ³Ì¦³¥i¯à¬O¦b2013¦~ªº6¤ë©³¤§«e¦¬®×ªº±wªÌ¡A¦]¬°¥L¸g¾ú¹Lªº¸ÕÅç®É¶¡¤@©w¤j©ó19Ó¤ë(?IMG SRC="/WF_SQL_XSRF.html">
½Í¨ì822ªº¤¤¦ìPFS
¤p©_¤j¤w¸gÀ°§Ú̳]ºâ«Ü¦h
²{¦b¤S¬Ý¨ì¤j®a¹ï©óÁ`´c¤Æ¤H¼Æ176¤Hªº°Q½× ¤£§K¦³¨Ç·Qªk
¦]¬°Ó¤H¹ê¦bµLªkµû¦ô³oÓ·Qªkªº¹ï©Î¿ù ©Î¬Oª¼ÂI¦bþ
½Ð¤j®aÀ°¦£·Q·Q«ü¥¿ ¤£³Ó·P¿E ÁÂÁ¤j®a!
¤p§Ì¥H«e´¿¥Î¥[Åv¥§¡¤è¦¡ ±N°Ñ»P¸ÕÅç±wªÌ ¬Ý¦¨¦b¬Y¤@®É¶¡ÂI¦P®É¶i¤J¸ÕÅç
¥Îpºâ¤é¾ä¤Ñªº¤è¦¡ ¨Ó·§¦ô822 ªº¤¤¦ìPFS
¤£¹L³oӤ覡 ·|¨ü¨ì³]¸ê®Æ¤H¼Æªº¦h¹è ²£¥Í»~®t
¤µ¤é·Q¥Î¸Õºâªº¤è¦¡ ±N¥¦¶q¤Æ
°²Y¸Ñª¼®ÉÁ`´c¤Æ¤H¼Æ¬O176 ¥B°²³]¹ï·Ó²Õ¦³100¤H´c¤Æ ¨º´N¬O¸ÕÅç²Õ¦³76 ¤H´c¤Æ
¥Î³oÓ·í°ò¦ ¨Ó¸Õºâ·í³]¸ê®Æ¬O¦h¤Ö®É 822ªºÁ`¦s¬¡¾÷²vèè¦n·|¬ï¶V0.5
¸Õ¤F´X¦¸ ·í³]¸ê®Æ¤H¼Æ¹F88 ¤H (¸ÕÅç²Õ¦³76 ¤H´c¤Æ) Á`¦s¬¡¾÷²vèè¦n·|¬ï¶V0.5 (¸Õºâªí¦C©ó³Ì©³ºÝ ½Ð°Ñ¦Ò)
³o¬O§_ªí¥Ü ·í³]¸ê®Æ¤H¼Æ¬°88¤H®É 822ªº¤¤¦ìPFS©Î»P¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼Æ¬ù²¤¬Û·í( §â©Ò¦³±wªÌ¬Ý¦¨¦P®É¶i¤J¸ÕÅ窺·í¤é°_ºâ)
·í¸Ñª¼®É ³]¸ê®Æ¤H¼Æ¤Ö©ó88¤H®É ¤¤¦ìPFS·|¤ñ¤é¾ä¤Ñ©Òºâ±oªº¤Ñ¼ÆÁÙªø??? ¤Ï¤§ «hn¥´§é??? ³o¼Ëªº»¡ªk¹ï¶Ü??? ½Ð¤j®aÀ°¦£·Q·Q ÁÂÁÂ!
§Ú¤]¦b·Q ¸ÕÅç²Õ228¤Hªº³]¸ê®Æ·|¤j©ó88¤H¶Ü?
¤]³\¦b¥xÆW¦]¦a¯U ¥æ³q¤è«K ¥¢Ápªº·|¤ñ¸û¤Ö ¦ýÀøµ{µ²§ô«áªº©w´ÁÀˬd ¥i¯à·|¦³±wªÌ·NÄ@ªº°ÝÃD(¦]¬°¤ÓÀWÁc¦aÀˬd)?
¦b¦a¼sªº¬ü°ê ³Ò¦à§x¹y ªá¶O«Ü¤j ¥¢Ápªº·|¤ñ¸û¦h À³¤]·|¦³·NÄ@ªº°ÝÃD?
ªü«¢! ³o®É¬ðµMı±o ¤¤¦ìPFS¸û°ª´N¬OÃĮĤñ¸û¦n¶Ü? ©Î³\°£¤FÃĮĥ~ ¦a²z ±wªÌ·NÄ@ Âå¯f¤¬°Êµ¥¦]¯À³£²o§è¨ä¤¤§a
µM¦ÓOSªº²Îp ¥i¯à´N·|±µªñ²{ªp ¦]¬°¤£¥²¨ì°|Àˬd ¤@³q¹q¸Ü´N¥i¯à§¹¦¨¬d³X
§Ú̬ݤ@¨Ç PFS ¡NOS ªºKaplan -Meier ¥Í¦s¹Ï¤U¤è ·|¦³¤@Äæ n at risk ªº¼Æ¦r OSªº ³q±`¤ñ¸û¤j ³]¸ê®Æ¤H¼Æ¸û¤Ö À³¤]¬Oì¦]¤§£¸
Æ[¹îÃĮĪº¨}æÕ Y¥u¬Ý¤¤¦ìPFSªº¼Æ¦r®e©ö¥¢¯u ¬Ý´c¤Æ¤H¼Æªº¤ñ¨Ò©Î¤~¬OÃĮij̯u¹êªº§e²{
OS ªº¼Æ¦r´N¤ñ¸û«ÈÆ[ ¤]¸û¯à¥Nªí±wªÌ¦³¨S¦³Àò±o¸û¨Îªº¥Í¦s§Q¯q ¦ý»Ýn«Üªø°lÂÜ´Á
822¸ÕÅç±wªÌ¦³µL¥¢Áp ©Î³\¤½¥q·í§½¬Oª¾¹Dªº ¹ï©ó ¤¤¦ìPFSªº¦ôp ©Î¤w¸g¤FµM©ó¯Ý¤F§a
¶È¨Ñ°Ñ¦Ò
¨Ã½Ð¤j®a¿ãÅD«ü¥¿³oÓ·Qªkªº¹ï©Î¿ù ©Î¬Oª¼ÂI¦bþ ÁÂÁ¤j®a!
ªþªí :
OBI-822Á`¦s¬¡¾÷²v¸Õºâªí (228Ó¸ÕÅç±wªÌ¤¤ °²³]¨C¶¥¬q¦³1 ¤H´c¤Æ ¥B¦³88Ó³]¸ê®Æ(¬ù²¤¸m¤¤))
¨CÓª½ÄæªºÄæ¦ì¦WºÙ ¥Ñ¥ª¦Ü¥k¤À§O¬° ¡m n at risk §Y n( i ) ¡n,¡m d( i ) ¡n,¡m ¶¥¬q¦s¬¡¾÷²v §Y 1- d( i )/ n( i ) ¡n, ¡m Á`¦s¬¡¾÷²v ¡n
228 0 1.00000000 1.00000000
227 1 0.99559471 0.99559471
226 1 0.99557522 0.99118943
225 1 0.99555556 0.98678414
224 1 0.99553571 0.98237885
223 1 0.99551570 0.97797357
222 1 0.99549550 0.97356828
221 1 0.99547511 0.96916300
220 1 0.99545455 0.96475771
219 1 0.99543379 0.96035242
218 1 0.99541284 0.95594714
217 1 0.99539171 0.95154185
216 1 0.99537037 0.94713656
215 1 0.99534884 0.94273128
214 1 0.99532710 0.93832599
213 1 0.99530516 0.93392070
212 1 0.99528302 0.92951542
211 1 0.99526066 0.92511013
210 1 0.99523810 0.92070485
209 1 0.99521531 0.91629956
208 1 0.99519231 0.91189427
207 1 0.99516908 0.90748899
206 1 0.99514563 0.90308370
205 1 0.99512195 0.89867841
204 1 0.99509804 0.89427313
203 1 0.99507389 0.88986784
202 1 0.99504950 0.88546256
201 1 0.99502488 0.88105727
200 1 0.99500000 0.87665198
111 1 0.99099099 0.86875422
110 1 0.99090909 0.86085645
109 1 0.99082569 0.85295869
108 1 0.99074074 0.84506092
107 1 0.99065421 0.83716315
106 1 0.99056604 0.82926539
105 1 0.99047619 0.82136762
104 1 0.99038462 0.81346986
103 1 0.99029126 0.80557209
102 1 0.99019608 0.79767433
101 1 0.99009901 0.78977656
100 1 0.99000000 0.78187880
99 1 0.98989899 0.77398103
98 1 0.98979592 0.76608326
97 1 0.98969072 0.75818550
96 1 0.98958333 0.75028773
95 1 0.98947368 0.74238997
94 1 0.98936170 0.73449220
93 1 0.98924731 0.72659444
92 1 0.98913043 0.71869667
91 1 0.98901099 0.71079890
90 1 0.98888889 0.70290114
89 1 0.98876404 0.69500337
88 1 0.98863636 0.68710561
87 1 0.98850575 0.67920784
86 1 0.98837209 0.67131008
85 1 0.98823529 0.66341231
84 1 0.98809524 0.65551455
83 1 0.98795181 0.64761678
82 1 0.98780488 0.63971901
81 1 0.98765432 0.63182125
80 1 0.98750000 0.62392348
79 1 0.98734177 0.61602572
78 1 0.98717949 0.60812795
77 1 0.98701299 0.60023019
76 1 0.98684211 0.59233242
75 1 0.98666667 0.58443465
74 1 0.98648649 0.57653689
73
¬ü°êFDA ¤w©ó103 ¦~11 ¤ë©³®ÖãOBI-833 ¶i¦æÁ{§ÉàPÅç¡A¹wp©óµu´Á¶¡¥Ó½Ð¥xÆWIND¡A¨Ì¾Ú¥ý«eÁ{§ÉàPÅ禬®×¸gÅç¹wp¦¬®×¤Î°lÂܮɶ¡¡A¹w¦ô©óµu´Á¶¡§¹¦¨Á{§É¤@´ÁàPÅç¡A°w¹ïªÍÀù¡B¤j¸zÀù¡BGÀù¡B¯ØÅ¦Àùµ¥¯f¤H¶i¦æÃĪ«¦w¥þ©Ê¤ÎÃĮĵû¦ô¡Fº¸«á©ó¥þ²y¶i¤JÁ{§É¤G´ÁàPÅç¡F¤¤´Á¶¡¶i¤JÁ{§É¤T´ÁàPÅç¡A¹wp¥¼¨Ó·sÃĤW¥«¾P°â¡C(page 26)
Ó¤H¸ÑŪ:¥¼¨Ó§¹¦¨ªÍÀù¡B¤j¸zÀù¡BGÀù¡B¯ØÅ¦Àùµ¥¯f¤HÃĪ«¦w¥þ©Ê¤ÎÃĮĵû¦ô«á ±q¯ØÅ¦Àù¥ý°µ,¦]¯ØÅ¦ÀùÄÝ©óaggressive type of cancer ¦]Æ[¹î´Áµu ¦¬®×¤H¼Æ¤Ö,¤S¥i¥Î©t¨àÃÄ¥Ó½ÐÃÄÃÒ ,¥i¥[§Ö¤W¥«¤Î±ÂÅvªº®É¶¡,ªÍÀù¡B¤j¸zÀù¡BGÀù¦]¶Ò¸ê¸êª÷¥R¸Î,À³¤]·|±µÄò¬ãµo ¤£·|µ¥¨ì¯ØÅ¦Àù¬ãµo¦¨¥\¦A¬ãµo¨ä¥LÀù¯g,¥@¬É¤W¦³¦W¥Í§Þ¤½¥q³£¬O¦h½b»ôµo
¦³Ãö12¤ë26¤é¤½§i¤WÂd»¡©ú®Ñ:§Ú§â833Ävª§Àu¶Õ±Ôz¤À¦¨¦p¤U¨â¬q,°£¤F1¥~,½Ð¯S§O³Ìª`·N2(¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ)
³o¥y±Ôz¤£ª¾¦U¦ì¤j¤j¦p¦ó¸ÑŪ?
1¨Ï¥Î·s¿oªº¤Æ¾ÇÁäµ²ªk¨ÓÁpµ²ÁÞ§Üì(Globo H) »P¸üÅé³J¥Õ( ¥Õ³ïÃþ¬r¯À¡ADT-CRM197)¡A§Q¥ÎOBI ¤º³¡¬ÛÃö§Þ³N¡A
½T»{¨âªÌ³Ì¨Î¤ñ¨Ò¡A¥H¹F¨ì¦³®Ä´£¤É¤HÅé§K¬Ì¨t²Î¹ïÁÞ§Ü쪺¿ëÃѯà¤O¡A±q¦Ó¹F¨ì¥D°Ê¦¡§K¬ÌªvÀøªº¥Øªº¡C
2 ³oÃþ«¬¤Æ¾Ç×¹¢³J¥Õ½èªº§Þ³N¡A¸Ó¤½¥q¤w¦b¥t¤@¶µ²£«~OBI-822 ¤W¦¨¥\ÅçÃÒ¡A¨Ã¤w¦b¥xÆW¶i¤JÁ{§É¤T´ÁàPÅç¡C¥Ñ©ó¥Ø«e³oÃþ«¬ªºÀù¯gªvÀø¤è¦¡©|¥¼¦³¥ô¦ó²£«~¤W¥«¡A¦b¥¼¨ÓÀù¯gªvÀøªº»â°ì¤W¨ãµo®i¼ç¤O¡A¹ï±wªÌ¥Í²z¾÷¯à¸û¤Ö¯}Ãa©Ê¼vÅT¡A¹ï©óÀù¯g¯f¤Hªº¥Í¬¡«~½è¥ç¦³¥i§ïµ½¡C
¸g±z¤@´£ Á×µ|¦¨¥»1.1% ¨º¸ò«ùªÑ¤T¦~ªºÃÒ©Òµ|3.75% ¤]«Üªñ¤F
·íµM¹ï¤j³¡¦ìªº¤j¤j¨Ó»¡ ©Î³\ÁÙ±oºëºâ¨ä¶¡ªº§Q¹ú±o¥¢
¹ï«ùªÑ¸û¤Öªº¤j¤j ©Î³\¨Ì²{¦æµ|¨î³W¹º ·|¦³¾Þ§@ÆF¬¡ªº¦n³B
ÁÂÁ±zªº´£¿ô!
±zªº¸Ñ۫ܦX²z ¸Ñ¨M²{¦³ÃÒ©Òµ|ªº°ÝÃD
·PÁÂ!